GLP-1Approved 2005

Exenatide

Last updated

GLP-1 receptor agonist. Twice daily (Byetta); once weekly (Bydureon BCise).

Byetta (discontinued), Bydureon BCise (discontinued), Generic exenatide·AstraZeneca

Other GLP-1 medicines at sellers we link to

  • Lowest compounded tirzepatide on a monthly plan, not FDA-approved

    Collective

    $69/mo + $199/yr membership · about $86 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest compounded semaglutide on a monthly plan, not FDA-approved

    Collective

    $59/mo + $199/yr membership · about $76 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

No seller we link to sells exenatide; these are different medicines, compounded and not FDA-approved. Those sellers pay us if you buy, which never changes a price we show.

Catalog reviewed Nov 4, 2026. Feed checks and price reviews are dated separately below. How we verify. Not medical advice.

Data updated . What changed

AstraZeneca discontinued both branded products in October 2024 (Byetta and Bydureon BCise), and the FDA withdrew their approvals as no longer marketed: Byetta and Bydureon on September 3, 2025, and Bydureon BCise on April 8, 2026. Amneal's generic exenatide, launched in 2025, is now listed by the FDA as discontinued too, so only remaining stock is still dispensed. Retained here for first-in-class historical context.

Average A1c drop in its main trial

DURATION-130 wks
−1.9 points (pubmed.ncbi.nlm.nih.gov/18782641)

A1c shows average blood sugar over about three months. From one trial, not a head-to-head ranking.

What the FDA label says

  • Generic exenatide injectionGlucose control in adults with type 2 diabetes. FDA label (dailymed.nlm.nih.gov)
Information from FDA labels and published trials, not medical advice.

What to know about Exenatide

An ingredient can have several brands, formulations, and approved uses. Prices and trial findings belong to the specific product and dose shown.

Sourced starting quote

~$422 per pen (goodrx.com/exenatide)

Days of supply not on record; not ranked per 30 days.

Checked on goodrx.com

Generic exenatide (Amneal)

GoodRx · GoodRx coupon, lowest listed price for one 5 mcg pen (60 doses: 30 days at the twice-daily dose)

Price conditions

GoodRx coupon, lowest listed price for one 5 mcg pen (60 doses: 30 days at the twice-daily dose)

Every exenatide product is now discontinued: the FDA withdrew the Byetta and Bydureon approvals in 2025, and Amneal's generic is listed by the FDA as discontinued too. Pharmacies may still dispense remaining stock.

Quote at the cited trial dose

No sourced quote available.

FDA-approved offers only in this summary. Starting and trial-dose quotes may cover different products. Every cash quote was checked on or after . Confirm eligibility, dose, fees, and supply length with the provider.

Mean weight change in the cited trial
≈−4% (diabetesjournals.org/care/article/33/6/1255/27340/DURATION-1-Exenatide-Once-Weekly-Produces) (-4.1 kg (~4% of the 102 kg baseline) at 52 wks · DURATION-1 · 2 mg weekly (Bydureon))

DURATION-1 · 2 mg weekly (Bydureon)

A1c reduction in the cited trial
−1.9 pp (pubmed.ncbi.nlm.nih.gov/18782641) (-1.9% at 30 wks · DURATION-1 · HbA1c change in percentage points)

DURATION-1

Stopped treatment for adverse events
3.9% (accessdata.fda.gov/drugsatfda_docs/label/2024/209210s024lbl.pdf) (3.9% discontinued for adverse reactions · Bydureon BCise FDA label (2 mg, type 2 diabetes))

Bydureon BCise FDA label (2 mg, type 2 diabetes)

FDA shortage report
No shortage reported

No matching shortage record was returned in the latest complete FDA check.

Route & frequency
Twice daily (Byetta); once weekly (Bydureon BCise)

Trial averages are not personal predictions. Weight-loss, A1c, and side-effect figures may come from different trials, doses, or populations; follow each source for its context.

Where to get it

Ways to get Exenatide

Compare sourced starting and maintenance-dose prices. Compounded products and membership fees are labeled separately.

1 current price

  • Generic exenatide (Amneal)

    GoodRx

    View
    ~$422 per pen (goodrx.com/exenatide)

    Checked on goodrx.com

    Third-party report

    Top dose: No separate price on record

    Terms & source

    Advertised price: GoodRx coupon, lowest listed price for one 5 mcg pen (60 doses: 30 days at the twice-daily dose)

    Days of supply not on record; not ranked per 30 days.

    Every exenatide product is now discontinued: the FDA withdrew the Byetta and Bydureon approvals in 2025, and Amneal's generic is listed by the FDA as discontinued too. Pharmacies may still dispense remaining stock.

    Confirm the prescribed dose, supply length, membership or consultation fees, and refill conditions with the seller. A listed offer does not confirm eligibility or stock.

    Ingredient-level FDA shortage report:No shortage reportedOpen record
    Advertised price as read on its own page (goodrx.com)

Read prices in context. Compare the same product, dose and payment terms; missing prices are not estimated.

How prices are compared

A prepaid monthly rate is not a monthly payment. Cost order uses current, recently checked quotes, converted to 30 days: by the supply a price buys where the seller states it in days, otherwise a monthly price with its plan length on record read as four weekly doses, a yearly membership in the price spread over twelve months. Introductory prices, ranges, prices with no plan length on record and separately billed fees are unranked references. Dose changes and added fees affect what you pay.

A listed maintenance dose is not a dosing recommendation.

Prices are self-pay cash figures a person pays, not pharmacy acquisition costs. They change often; each names its source. Every cash quote was checked on or after Nov 6, 2026. Compounded semaglutide and tirzepatide are prepared by pharmacies and are not FDA-approved. This is information, not medical advice.

Indications

Brands, formulations & approved uses

Byetta (discontinued)

  • Injection (historical brand)Twice daily, before meals

    Historical label: glucose control in adults with type 2 diabetes. This discontinued brand is retained for reference, not as a current access option.

    Prescribing information (dailymed.nlm.nih.gov) · Reviewed Sep 22, 2026

Bydureon BCise (discontinued)

  • Extended-release injection (historical brand)Once weekly

    Historical label: glucose control in adults and children 10+ with type 2 diabetes. This discontinued brand is retained for reference, not as a current access option.

    Prescribing information (accessdata.fda.gov) · Reviewed Sep 22, 2026

Generic exenatide

  • InjectionTwice daily, before meals

    Glucose control in adults with type 2 diabetes.

    Prescribing information (dailymed.nlm.nih.gov) · Reviewed Nov 4, 2026

The first-in-class GLP-1 receptor agonist, a synthetic version of exendin-4, available in twice-daily and extended-release once-weekly forms.

Availability

Shortage status

No shortage reported

No matching shortage record was returned in the latest complete FDA check. Check the FDA database (accessdata.fda.gov).

Last complete check: Nov 17, 2026

Pricing

Pharmacy acquisition-cost reference

NADAC measures pharmacy acquisition costs per unit, not what you pay. Different strengths and concentrations are not equivalent monthly supplies.

View pharmacy and policy price references
  • Exenatide 10 MCG Dose Pen Inj
    NDC 70121168601
    Acquisition
    $300.1675/mL (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d)
    Effective Jul 22, 2026
    CMS release Nov 11, 2026
    Checked Nov 16, 2026

Source: NADAC (Data.Medicaid.gov) (data.medicaid.gov/api/1/datastore/query/5145182d-8c6e-5464-a999-819ce26b0e2d) · as of Nov 16, 2026

The ingredient index tracks pharmacy acquisition costs over windows up to 53 days long, not patient cash prices or just the presentation listed above. Each NDC starts at 100; we average its percentage change with the same NDCs at every point, so per-tablet and per-mL dollar prices are never averaged together. Incomplete days are omitted. “Flat” means a change smaller than 0.5%. Insufficient or truncated history shows no index.

NADAC is the average price pharmacies pay to acquire a drug, not the cash price at the counter. Compounded and cash prices, where shown, are labeled and are not FDA-approved list prices.
Product labeling

Dosing, warnings & contraindications

Choose the named product and route. These are submitted label records, which may differ from current approved prescribing information. The product links above lead to current prescribing information. Indexed text omits tables and images; always read the full source label.

Showing the most recently effective indexed record for each brand and route combination. Alternate submissions and older records are linked below.

Byetta

SUBCUTANEOUS · AstraZeneca Pharmaceuticals LP

Label effective · version 26Retrieved · Nov 17, 2026 UTCFull label on DailyMed (dailymed.nlm.nih.gov)Indexed source record (api.fda.gov)
Read indexed warnings and label text

Boxed warning

This section was not supplied in the indexed record. Check the full source label.

Contraindications

4 CONTRAINDICATIONS BYETTA is contraindicated in patients with: • A prior severe hypersensitivity reaction to exenatide or to any of the excipients in BYETTA. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with BYETTA [see Warnings and Precautions (5.7) ]. • A history of drug-induced immune-mediated thrombocytopenia from exenatide products. Serious bleeding, which may be fatal, from drug-induced immune-mediated thrombocytopenia has been reported with exenatide use [see Warnings and Precautions (5.8) ] . • History of severe hypersensitivity to exenatide or any of the excipients in BYETTA. (4) • History of drug-induced immune-mediated thrombocytopenia from exenatide products. ( 4 )

Indications and uses

1 INDICATIONS AND USAGE BYETTA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use • BYETTA contains exenatide. Coadministration with other exenatide-containing products is not recommended. BYETTA (exenatide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 , 14 ) Limitations of Use • Coadministration with other exenatide-containing products is not recommended ( 1 ).

Dosing and administration

2 DOSAGE AND ADMINISTRATION • Inject subcutaneously within 60 minutes prior to morning and evening meals (or before the two main meals of the day, approximately 6 hours or more apart). ( 2.1 ) • Initiate at 5 mcg per dose twice daily; increase to 10 mcg twice daily after 1 month based on clinical response. ( 2.1 ) 2.1 Recommended Dosing • Initiate BYETTA at 5 mcg administered subcutaneously twice daily at any time within the 60-minute period before the morning and evening meals (or before the two main meals of the day, approximately 6 hours or more apart). Do not administer after a meal. • Based on clinical response, the dose of BYETTA can be increased to 10 mcg twice daily which is recommended after 1 month of therapy, in order to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions (5.5) and Adverse Reactions (6.1) ] . • Administer as a subcutaneous injection in the thigh, abdomen, or upper arm. • Rotate injections sites with each dose. Do not use the same site for each injection. • Inspect visually for particulate matter and discoloration. Only use BYETTA if the solution appears clear, colorless, and contains no particles. • When using BYETTA with insulin, administer as separate injections and never mix. It is acceptable to inject BYETTA and insulin in the same body region, but the injections should not be adjacent to each other. • If a dose is missed, resume the treatment regimen as prescribed with the next scheduled dose. 2.1 Recommended Dosing • Initiate BYETTA at 5 mcg administered subcutaneously twice daily at any time within the 60-minute period before the morning and evening meals (or before the two main meals of the day, approximately 6 hours or more apart). Do not administer after a meal. • Based on clinical response, the dose of BYETTA can be increased to 10 mcg twice daily which is recommended after 1 month of therapy, in order to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions (5.5) and Adverse Reactions (6.1) ] . • Administer as a subcutaneous injection in the thigh, abdomen, or upper arm. • Rotate injections sites with each dose. Do not use the same site for each injection. • Inspect visually for particulate matter and discoloration. Only use BYETTA if the solution appears clear, colorless, and contains no particles. • When using BYETTA with insulin, administer as separate injections and never mix. It is acceptable to inject BYETTA and insulin in the same body region, but the injections should not be adjacent to each other. • If a dose is missed, resume the treatment regimen as prescribed with the next scheduled dose.

Warnings and precautions

5 WARNINGS AND PRECAUTIONS • Acute Pancreatitis : Has been observed in patients treated with GLP-1 receptor agonists, including BYETTA. Discontinue if pancreatitis is suspected. ( 5.1 ) • Never share a BYETTA pen between patients, even if the needle is changed. ( 5.2 ) • Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: Patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. Reduction in the dose of insulin secretagogues or insulin may be necessary. ( 5.3 ) • Acute Kidney Injury Due to Volume Depletion : Monitor renal function in patients reporting adverse reactions that could lead to volume depletion ( 5.4 ) • Severe Gastrointestinal Adverse Reactions : Use has been associated with gastrointestinal adverse reactions, sometimes severe. BYETTA is not recommended in patients with severe gastroparesis. ( 5.5 ) • Immunogenicity: Patients may develop antibodies to exenatide. If there is worsening glycemic control or failure to achieve target glycemic control, consider alternative antidiabetic therapy. ( 5.6 ) • Hypersensitivity: Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue BYETTA and promptly seek medical advice. ( 5.7 ) • Drug-induced Immune-mediated Thrombocytopenia: Serious bleeding which may be fatal has been reported. Discontinue BYETTA promptly and avoid re-exposure to exenatide. ( 5.8 ) • Acute Gallbladder Disease: If cholelithiasis or cholecystitis are suspected, gallbladder studies are indicated. ( 5.9 ) • Pulmonary Aspiration During General Anesthesia or Deep Sedation: Has been reported in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures. Instruct patients to inform healthcare providers of any planned surgeries or procedures. ( 5.10 ) 5.1 Acute Pancreatitis Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with glucagon-like peptide-1 (GLP-1) receptor agonists, including BYETTA [see Adverse Reactions (6.2) ] . After initiation of BYETTA, observe patients carefully for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting). If pancreatitis is suspected, discontinue BYETTA and initiate appropriate management. 5.2 Never Share a BYETTA Pen Between Patients BYETTA pens must never be shared between patients, even if the needle is changed. Pen-sharing poses a risk for transmission of blood-borne pathogens. 5.3 Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin Patients receiving BYETTA in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia including severe hypoglycemia [see Adverse Reactions (6) and Drug Interactions (7) ] . The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia. 5.4 Acute Kidney Injury Due to Volume Depletion There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists, BYETTA [see Adverse Reactions (6.2) ] . The majority of the reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea [see Adverse Reactions (6) ] . Monitor renal function in patients reporting adverse reactions to BYETTA that could lead to volume depletion, especially during dosage initiation and escalation of BYETTA. BYETTA is not recommended in patients with severe renal impairment (creatinine clearance <30 mL/min) or end-stage renal disease and should be used with caution in patients with renal transplantation [see Use in Specific Populations (8.6) ] . 5.5 Severe Gastrointestinal Adverse Reactions Use of GLP-1 receptor agonists, including BYETTA, has been associated with gastrointestinal adverse reactions, sometimes severe [see Adverse Reactions (6) ] . BYETTA is not recommended in patients with severe gastroparesis. 5.6 Immunogenicity Patients may develop antibodies to exenatide following treatment with BYETTA. Antibody levels were measured in 90% of subjects in the 30-week, 24-week, and 16-week placebo-controlled studies and the 30-week comparator-controlled study of BYETTA. In 3%, 4%, 1%, and 1% of these patients, respectively, antibody formation was associated with an attenuated glycemic response. If there is worsening glycemic control or failure to achieve targeted glycemic control, alternative antidiabetic therapy should be considered [see Adverse Reactions (6.1) ] . 5.7 Hypersensitivity There have been postmarketing reports of serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) in patients treated with BYETTA. If a hypersensitivity reaction occurs, the patient should discontinue BYETTA and other suspect medications and promptly seek medical advice. Inform and closely monitor patients with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist for allergic reactions, because it is unknown whether such patients will be predisposed to anaphylaxis with BYETTA [see Adverse Reactions (6.2) ] . 5.8 Drug-Induced Thrombocytopenia Serious bleeding, which may be fatal, from drug-induced immune-mediated thrombocytopenia has been reported in the postmarketing setting with exenatide use. Drug-induced thrombocytopenia is an immune-mediated reaction, with exenatide-dependent anti-platelet antibodies. In the presence of exenatide, these antibodies cause platelet destruction. If drug-induced thrombocytopenia is suspected, discontinue BYETTA immediately and do not re-expose the patient to exenatide [see Adverse Reactions (6.2) ] . 5.9 Acute Gallbladder Disease Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing. In a clinical study with exenatide, 1.9% of exenatide-treated patients and 1.4% of placebo-treated patients reported an acute event of gallbladder disease, such as cholelithiasis or cholecystitis. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated. 5.10 Pulmonary Aspiration During General Anesthesia or Deep Sedation BYETTA delays gastric emptying [ see Clinical Pharmacology (12.2) ]. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations. Available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking BYETTA, including whether modifying preoperative fasting recommendations or temporarily discontinuing BYETTA could reduce the incidence of retained gastric contents. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking BYETTA. 5.1 Acute Pancreatitis Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with glucagon-like peptide-1 (GLP-1) receptor agonists, including BYETTA [see Adverse Reactions (6.2) ] . After initiation of BYETTA, observe patients carefully for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting). If pancreatitis is suspected, discontinue BYETTA and initiate appropriate management. 5.2 Never Share a BYETTA Pen Between Patients BYETTA pens must never be shared between patients, even if the needle is changed. Pen-sharing poses a risk for transmission of blood-borne pathogens. 5.3 Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin Patients receiving BYETTA in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia including severe hypoglycemia [see Adverse Reactions (6) and Drug Interactions (7) ] . The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia. 5.4 Acute Kidney Injury Due to Volume Depletion There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists, BYETTA [see Adverse Reactions (6.2) ] . The majority of the reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea [see Adverse Reactions (6) ] . Monitor renal function in patients reporting adverse reactions to BYETTA that could lead to volume depletion, especially during dosage initiation and escalation of BYETTA. BYETTA is not recommended in patients with severe renal impairment (creatinine clearance <30 mL/min) or end-stage renal disease and should be used with caution in patients with renal transplantation [see Use in Specific Populations (8.6) ] . 5.5 Severe Gastrointestinal Adverse Reactions Use of GLP-1 receptor agonists, including BYETTA, has been associated with gastrointestinal adverse reactions, sometimes severe [see Adverse Reactions (6) ] . BYETTA is not recommended in patients with severe gastroparesis. 5.6 Immunogenicity Patients may develop antibodies to exenatide following treatment with BYETTA. Antibody levels were measured in 90% of subjects in the 30-week, 24-week, and 16-week placebo-controlled studies and the 30-week comparator-controlled study of BYETTA. In 3%, 4%, 1%, and 1% of these patients, respectively, antibody formation was associated with an attenuated glycemic response. If there is worsening glycemic control or failure to achieve targeted glycemic control, alternative antidiabetic therapy should be considered [see Adverse Reactions (6.1) ] . 5.7 Hypersensitivity There have been postmarketing reports of serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) in patients treated with BYETTA. If a hypersensitivity reaction occurs, the patient should discontinue BYETTA and other suspect medications and promptly seek medical advice. Inform and closely monitor patients with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist for allergic reactions, because it is unknown whether such patients will be predisposed to anaphylaxis with BYETTA [see Adverse Reactions (6.2) ] . 5.8 Drug-Induced Thrombocytopenia Serious bleeding, which may be fatal, from drug-induced immune-mediated thrombocytopenia has been reported in the postmarketing setting with exenatide use. Drug-induced thrombocytopenia is an immune-mediated reaction, with exenatide-dependent anti-platelet antibodies. In the presence of exenatide, these antibodies cause platelet destruction. If drug-induced thrombocytopenia is suspected, discontinue BYETTA immediately and do not re-expose the patient to exenatide [see Adverse Reactions (6.2) ] .

Drug interactions

7 DRUG INTERACTIONS • May impact absorption of orally administered medications. ( 7 ) • Warfarin: Postmarketing reports of increased INR sometimes associated with bleeding. Monitor INR frequently until stable upon initiation or alteration of BYETTA therapy. ( 7 ) Generic Section Table 6: Clinically Relevant Interactions with BYETTA Concomitant Use of Insulin Secretagogues or Insulin Clinical Impact Exenatide promotes insulin release from pancreatic beta-cells in the presence of elevated glucose concentrations. The risk of hypoglycemia is increased when exenatide is used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin [see Warnings and Precautions (5.3) and Adverse Reactions (6) ] . Intervention When initiating BYETTA, consider reducing the dose of concomitantly administered insulin secretagogue or insulin to reduce the risk of hypoglycemia. Warfarin Clinical Impact In a drug interaction study, BYETTA did not have a significant effect on INR [see Clinical Pharmacology (12.3) ] . There have been postmarketing reports for BYETTA of increased INR with concomitant use of warfarin, sometimes associated with bleeding [see Adverse Reactions (6.2) ] . Intervention In patients taking warfarin, the prothrombin time should be monitored more frequently after initiation or alteration of BYETTA therapy. Once a stable prothrombin time has been documented, the prothrombin time can be monitored at the intervals recommended for patients taking warfarin. Orally Administered Drugs (e.g., acetaminophen) Clinical Impact Exenatide slows gastric emptying. Therefore, BYETTA has the potential to reduce the rate of absorption of orally administered drugs [see Clinical Pharmacology (12.3) ]. Intervention Use caution when administering oral medications with BYETTA where a slower rate of oral absorption may be clinically meaningful. For oral medications that are dependent on threshold concentrations for efficacy, such as contraceptives and antibiotics, patients should be advised to take those drugs at least 1 hour before BYETTA injection. If such drugs are to be administered with food, patients should be advised to take them with a meal or snack when BYETTA is not administered [see Clinical Pharmacology (12.3) ] .

Adverse reactions

6 ADVERSE REACTIONS The following serious adverse reactions are described below or elsewhere in the prescribing information: • Acute Pancreatitis [see Warnings and Precautions (5.1) ] • Never Share a BYETTA Pen Between Patients [see Warnings and Precautions (5.2) ] • Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3) ] • Acute Kidney Injury Due to Volume Depletion [see Warnings and Precautions (5.4) ] • Severe Gastrointestinal Adverse Reactions [see Warnings and Precautions (5.5) ] • Immunogenicity [see Warnings and Precautions (5.6) ] • Hypersensitivity [see Warnings and Precautions (5.7) ] • Drug-Induced Thrombocytopenia [see Warnings and Precautions (5.8) ] • Acute Gallbladder Disease [see Warnings and Precautions (5.9) ] • Pulmonary Aspiration During General Anesthesia or Deep Sedation [see Warnings and Precautions (5.10) ] • Most common (≥5%) and occurring more frequently than placebo in clinical trials: nausea, hypoglycemia, vomiting, diarrhea, feeling jittery, dizziness, headache, dyspepsia, constipation, asthenia. Nausea usually decreases over time. ( 5.3 , 6 ) To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1-800-236-9933 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Hypoglycemia Table 1 summarizes the incidence and rate of hypoglycemia with BYETTA in six placebo-controlled clinical trials. Table 1: Incidence (%) and Rate of Hypoglycemia when BYETTA was used as Monotherapy or with Concomitant Antidiabetic Therapy in Six Placebo-Controlled Clinical Trials A hypoglycemic episode was recorded if a patient reported symptoms of hypoglycemia with or without a blood glucose value consistent with hypoglycemia. Severe hypoglycemia was defined as an event with symptoms consistent with hypoglycemia requiring the assistance of another person and associated with either a documented blood glucose value <54 mg/dL or prompt recovery after treatment for hypoglycemia. Placebo BID BYETTA 5 mcg BID BYETTA 10 mcg BID Monotherapy (24 Weeks) N 77 77 78 % Overall 1.3% 5.2% 3.8% Rate (episodes/patient-year) 0.03 0.21 0.52 % Severe 0.0% 0.0% 0.0% With Metformin (30 Weeks) N 113 110 113 % Overall 5.3% 4.5% 5.3% Rate (episodes/patient-year) 0.12 0.13 0.12 % Severe 0.0% 0.0% 0.0% With a Sulfonylurea (30 Weeks) N 123 125 129 % Overall 3.3% 14.4% 35.7% Rate (episodes/patient-year) 0.07 0.64 1.61 % Severe 0.0% 0.0% 0.0% With Metformin and a Sulfonylurea (30 Weeks) N 247 245 241 % Overall 12.6% 19.2% 27.8% Rate (episodes/patient-year) 0.58 0.78 1.71 % Severe 0.0% 0.4% 0.0% With a Thiazolidinedione (16 Weeks) N 112 not evaluated 121 % Overall 7.1% not evaluated 10.7% Rate (episodes/patient-years) 0.56 not evaluated 0.98 % Severe 0.0% not evaluated 0.0% With Insulin Glargine with or without Metformin and/or Thiazolidinedione (30 Weeks) When BYETTA was initiated in combination with insulin glargine, the dose of insulin glargine was decreased by 20% in patients with an HbA 1c ≤8.0% to minimize the risk of hypoglycemia. See Table 9 for insulin dose titration algorithm. N 122 not evaluated 137 % Overall 29.5% not evaluated 24.8% Rate (episodes/patient-years) 1.58 not evaluated 1.61 % Severe 0.8% not evaluated 0.0% N = number of Intent-to-Treat subjects in each treatment group. Immunogenicity Antibodies were assessed in 90% of subjects in the 30-week, 24-week, and 16-week studies of BYETTA. In the 30-week controlled trials of BYETTA add-on to metformin and/or sulfonylurea, antibodies were assessed at 2- to 6-week intervals. The mean antibody titer peaked at Week 6 and was reduced by 55% by Week 30. Three hundred and sixty patients (38%) had low titer antibodies (<625) to exenatide at 30 weeks. The level of glycemic control (HbA 1c ) in these patients was generally comparable to that observed in the 534 patients (56%) without antibody titers. An additional 59 patients (6%) had higher titer antibodies (≥625) at 30 weeks. Of these patients, 32 (3% overall) had an attenuated glycemic response to BYETTA; the remaining 27 (3% overall) had a glycemic response comparable to that of patients without antibodies. In the 16-week trial of BYETTA add-on to thiazolidinediones, with or without metformin, 36 patients (31%) had low titer antibodies to exenatide at 16 weeks. The level of glycemic control in these patients was generally comparable to that observed in the 69 patients (60%) without antibody titer. An additional 10 patients (9%) had higher titer antibodies at 16 weeks. Of these patients, 4 (4% overall) had an attenuated glycemic response to BYETTA; the remaining 6 (5% overall) had a glycemic response comparable to that of patients without antibodies. In the 24-week trial of BYETTA used as monotherapy, 40 patients (28%) had low titer antibodies to exenatide at 24 weeks. The level of glycemic control in these patients was generally comparable to that observed in the 101 patients (70%) without antibody titers. An additional 3 patients (2%) had higher titer antibodies at 24 weeks. Of these patients, 1 (1% overall) had an attenuated glycemic response to BYETTA; the remaining 2 (1% overall) had a glycemic response comparable to that of patients without antibodies. Antibodies to exenatide were not assessed in the 30-week placebo-controlled trial of BYETTA used in combination with insulin glargine. In the 30-week comparator-controlled trial of BYETTA used in combination with insulin glargine and metformin, 60 patients (20%) had low titer antibodies to exenatide at 30 weeks. The level of glycemic control in these patients was generally comparable to that observed in the 234 patients (77%) without antibody titers. An additional 10 patients (3%) had higher titer antibodies at 30 weeks. Of these patients, 2 (1% overall) had an attenuated glycemic response to BYETTA; the remaining 8 (3% overall) had a glycemic response comparable to that of patients without antibodies. Two hundred and ten patients with antibodies to exenatide in the BYETTA clinical trials were tested for the presence of cross-reactive antibodies to GLP-1 and/or glucagon. No treatment-emergent cross-reactive antibodies were observed across the range of titers. Other Adverse Reactions Monotherapy For the 24-week placebo-controlled study of BYETTA used as a monotherapy, Table 2 summarizes adverse reactions (excluding hypoglycemia) occurring with an incidence ≥2% and occurring more frequently in BYETTA-treated patients compared with placebo-treated patients. Table 2: Treatment-Emergent Adverse Reactions ≥2% Incidence with BYETTA used as Monotherapy (excluding Hypoglycemia) In a 24-week placebo-controlled trial. Monotherapy Placebo BID N=77 % All BYETTA BID N=155 % Nausea 0 8 Vomiting 0 4 Dyspepsia 0 3 BID = twice daily. Adverse reactions reported in ≥1.0% to <2.0% of patients receiving BYETTA and reported more frequently than with placebo included decreased appetite, diarrhea, and dizziness. The most frequently reported adverse reaction associated with BYETTA, nausea, occurred in a dose-dependent fashion. Two of the 155 patients treated with BYETTA withdrew due to adverse reactions of headache and nausea. No placebo-treated patients withdrew due to adverse reactions. Cholelithiasis and cholecystitis In a clinical study with exenatide, 1.9% of exenatide-treated patients and 1.4% of placebo-treated patients reported an acute event of gallbladder disease, such as cholelithiasis or cholecystitis. Combination Therapy Add-On to Metformin and/or Sulfonylurea In the three 30-week controlled trials of BYETTA add-on to metformin and/or sulfonylurea, adverse reactions (excluding hypoglycemia) with an incidence ≥2% and occurring more frequently in BYETTA-treated patients compared with placebo-treated patients are summarized in Table 3. Table 3: Treatment-Emergent Adverse Reactions ≥2% Incidence and Greater Incidence with BYETTA Treatment used with Metformin and/or a Sulfonylurea (excluding Hypoglycemia) In three 30-week placebo-controlled clinical trials. Placebo BID N=483 % All BYETTA BID N=963 % Nausea 18 44 Vomiting 4 13 Diarrhea 6 13 Feeling Jittery 4 9 Dizziness 6 9 Headache 6 9 Dyspepsia 3 6 Asthenia 2 4 Gastroesophageal Reflux Disease 1 3 Hyperhidrosis 1 3 BID = twice daily Adverse reactions reported in ≥1.0% to <2.0% of patients receiving BYETTA and reported more frequently than with placebo included decreased appetite. Nausea was the most frequently reported adverse reaction and occurred in a dose-dependent fashion. With continued therapy, the frequency and severity decreased over time in most of the patients who initially experienced nausea. Patients in the long-term uncontrolled open-label extension studies at 52 weeks reported no new types of adverse reactions than those observed in the 30-week controlled trials. The most common adverse reactions leading to withdrawal for BYETTA-treated patients were nausea (3% of patients) and vomiting (1%). For placebo-treated patients, <1% withdrew due to nausea and none due to vomiting. Add-On to Thiazolidinedione with or without Metformin For the 16-week placebo-controlled study of BYETTA add-on to a thiazolidinedione, with or without metformin, Table 4 summarizes the adverse reactions (excluding hypoglycemia) with an incidence of ≥2% and occurring more frequently in BYETTA-treated patients compared with placebo-treated patients. Table 4: Treatment-Emergent Adverse Reactions ≥2% Incidence with BYETTA used with a Thiazolidinedione (TZD), with or without Metformin (MET) (excluding Hypoglycemia) In a 16-week placebo-controlled clinical trial. With a TZD or TZD/MET Placebo N=112 % All BYETTA BID N=121 % Nausea 15 40 Vomiting 1 13 Dyspepsia 1 7 Diarrhea 3 6 Gastroesophageal Reflux Disease 0 3 BID = twice daily. Adverse reactions reported in ≥1.0% to <2.0% of patients receiving BYETTA and reported more frequently than with placebo included decreased appetite. Chills (n=4) and injection-site reactions (n=2) occurred only in BYETTA-treated patients. The two patients who reported an injection-site reaction had high titers of antibodies to exenatide. Two serious adverse events (chest pain and chronic hypersensitivity pneumonitis) were reported in the BYETTA arm. No serious adverse events were reported in the placebo arm. The most common adverse reactions leading to withdrawal for BYETTA-treated patients were nausea (9%) and vomiting (5%). For placebo-treated patients, <1% withdrew due to nausea. Add-On to Insulin Glargine with or without Metformin and/or Thiazolidinedione (Placebo-Controlled) For the 30-week placebo-controlled study of BYETTA as add-on to insulin glargine with or without oral antihyperglycemic medications, Table 5 summarizes adverse reactions (excluding hypoglycemia) occurring with an incidence ≥2% and occurring more frequently in BYETTA-treated patients compared with placebo-treated patients. Table 5: Treatment-Emergent Adverse Reactions ≥2% Incidence with BYETTA used with Insulin Glargine with or without Oral Antihyperglycemic Medications (excluding Hypoglycemia) In a 30-week placebo-controlled clinical trial. With Insulin Glargine Placebo N=122 % All BYETTA BID N=137 % Nausea 8 41 Vomiting 4 18 Diarrhea 8 18 Headache 4 14 Constipation 2 10 Dyspepsia 2 7 Asthenia 1 5 Abdominal Distension 1 4 Decreased Appetite 0 3 Flatulence 1 2 Gastroesophageal Reflux Disease 1 2 BID = twice daily. The most frequently reported adverse reactions leading to withdrawal for BYETTA-treated patients were nausea (5.1%) and vomiting (2.9%). No placebo-treated patients withdrew due to nausea or vomiting. 6.2 Postmarketing Experience The following additional adverse reactions have been reported during post approval use of BYETTA or other formulations of exenatide. Because these events are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood : Drug induced thrombocytopenia. Drug Interactions : International normalized ratio (INR) increased with concomitant warfarin use sometimes associated with bleeding [see Drug Interactions (7) ] . Gastrointestinal : Nausea, vomiting, and/or diarrhea resulting in dehydration; abdominal distension, abdominal pain, eructation, constipation, flatulence, ileus, acute pancreatitis, hemorrhagic and necrotizing pancreatitis sometimes resulting in death Hepatobiliary : Cholecystitis, cholelithiasis requiring cholecystectomy. Hypersensitivity : Injection-site reactions, generalized pruritus and/or urticaria, macular or papular rash, angioedema, anaphylactic reaction. Neurologic : Dysgeusia, somnolence, dysesthesia. Pulmonary : Pulmonary aspiration has occurred in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation. Renal : Altered renal function, including increased serum creatinine, renal impairment, worsened chronic renal failure or acute renal failure (sometimes requiring hemodialysis), kidney transplant, and kidney transplant dysfunction. Skin and Subcutaneous Tissue : Alopecia.

Clinical studies

14 CLINICAL STUDIES BYETTA has been studied as monotherapy and in combination with metformin, a sulfonylurea, a thiazolidinedione, a combination of metformin and a sulfonylurea, a combination of metformin and a thiazolidinedione, or in combination with insulin glargine with or without metformin and/or thiazolidinedione. 14.1 Monotherapy In a randomized, double-blind, placebo-controlled trial of 24 weeks duration, BYETTA 5 mcg BID (n=77), BYETTA 10 mcg BID (n=78), or placebo BID (n=77) was used as monotherapy in patients with entry HbA1c ranging from 6.5% to 10%. All patients assigned to BYETTA initially received 5 mcg BID for 4 weeks. After 4 weeks, those patients either continued to receive BYETTA 5 mcg BID or had their dose increased to 10 mcg BID. Patients assigned to placebo received placebo BID throughout the trial. BYETTA or placebo was injected subcutaneously before the morning and evening meals. The majority of patients (68%) were White, 26% were West Asian, 3% were Hispanic or Latino ethnicity, 3% were Black or African American, and 0.4% were of East Asian ethnicity. The primary endpoint was the change in HbA 1c from baseline to Week 24 (or the last value at time of early discontinuation). Compared to placebo, BYETTA 5 mcg BID and 10 mcg BID resulted in statistically significant reductions in HbA 1c from baseline at Week 24 (Table 7). Table 7: Results of 24-Week Placebo-Controlled Trial of BYETTA used as Monotherapy Placebo BID BYETTA 5 mcg BID BYETTA 10 mcg BYETTA 5 mcg twice daily (BID) for 1 month followed by 10 mcg BID for 5 months before the morning and evening meals. BID Intent-to-Treat Population (N) 77 77 78 HbA 1c (%), Mean Baseline 7.8 7.9 7.8 Change at Week 24 Least squares means are adjusted for screening HbA1c strata and baseline value of the dependent variable. −0.2 −0.7 −0.9 Difference from placebo (95% CI) −0.5 [−0.9, −0.2] p <0.01, treatment vs. placebo. −0.7 [−1.0, −0.3] Proportion Achieving HbA 1c <7% 38% 48% 53% Body Weight (kg), Mean Baseline 86.1 85.1 86.2 Change at Week 24 −1.5 −2.7 −2.9 Difference from placebo (95% CI) −1.3 [−2.3, −0.2] −1.5 [−2.5, −0.4] Fasting Serum Glucose Measured using the hexokinase-based glucose method. (mg/dL), Mean Baseline 159 166 155 Change at Week 24 −5 −17 −19 Difference from placebo (95% CI) −12 [−23.2, −1.3] −14 [−24.5, −2.5] BID = twice daily. On average, there were no adverse effects of exenatide on blood pressure or lipids. 14.2 Combination Therapy with Oral Antihyperglycemic Medicines Three 30-week, double-blind, placebo-controlled trials were conducted to evaluate the safety and efficacy of BYETTA in patients with type 2 diabetes whose glycemic control was inadequate with metformin alone, a sulfonylurea alone, or metformin in combination with a sulfonylurea. In addition, a 16-week, placebo-controlled trial was conducted where BYETTA was added to existing thiazolidinedione (pioglitazone or rosiglitazone) treatment, with or without metformin, in patients with type 2 diabetes with inadequate glycemic control. In the 30-week trials, after a 4-week placebo lead-in period, patients were randomly assigned to receive BYETTA 5 mcg BID, BYETTA 10 mcg BID, or placebo BID before the morning and evening meals, in addition to their existing oral antidiabetic agent. All patients assigned to BYETTA initially received 5 mcg BID for 4 weeks. After 4 weeks, those patients either continued to receive BYETTA 5 mcg BID or had their dose increased to 10 mcg BID. Patients assigned to placebo received placebo BID throughout the study. A total of 1446 patients were randomized in the three 30-week trials: 991 (69%) were White, 224 (16%) were Hispanic or Latino and 174 (12%) were of Black of African American ethnicity. Mean HbA1c values at baseline for the trials ranged from 8.2% to 8.7%. In the placebo-controlled trial of 16 weeks duration, BYETTA (n=121) or placebo (n=112) was added to existing thiazolidinedione (pioglitazone or rosiglitazone) treatment, with or without metformin. Randomization to BYETTA or placebo was stratified based on whether the patients were receiving metformin. BYETTA treatment was initiated at a dose of 5 mcg BID for 4 weeks then increased to 10 mcg BID for 12 more weeks. Patients assigned to placebo received placebo BID throughout the study. BYETTA or placebo was injected subcutaneously before the morning and evening meals. In this trial, 79% of patients were taking a thiazolidinedione and metformin and 21% were taking a thiazolidinedione alone. The majority of patients (84%) were White, 8% were Hispanic or Latino ethnicity, and 3% were of Black or African American ethnicity. The mean baseline HbA1c values were 7.9% for BYETTA and placebo. The primary endpoint in each study was the mean change in HbA 1c from baseline to study end (or early discontinuation). Table 8 summarizes the study results for the 30- and 16-week clinical trials. Table 8: Results of 30-Week and 16-Week Placebo-Controlled Trials of BYETTA used in Combination with Oral Antidiabetic Agents Placebo BID BYETTA 5 mcg BID BYETTA 10 mcg BYETTA 5 mcg twice daily for 1 month followed by 10 mcg BID for 6 months for the 30-week trials or 10 mcg BID for 3 months in the 16-week trial before the morning and evening meals. BID In Combination with Metformin (30 Weeks) Intent-to-Treat Population (N) 113 110 113 HbA 1c (%), Mean Baseline 8.2 8.3 8.2 Change at Week 30 Least squares means are adjusted for baseline HbA 1c strata or value, investigator site, baseline value of the dependent variable (if applicable), and background antihyperglycemic therapy (if applicable). −0.0 −0.5 −0.9 Difference from placebo (95% CI) −0.5 [−0.7, −0.2] p <0.01, treatment vs. placebo. −0.9 [−1.1, −0.6] Proportion Achieving HbA 1c <7% 12% 32% 40% Body Weight (kg), Mean Baseline 99.9 100.0 100.9 Change at Week 30 −0.2 −1.3 −2.6 Difference from placebo (95% CI) −1.1 [−2.2, −0.0] −2.4 [−3.5, −1.3] Fasting Plasma Glucose Measured using the hexokinase-based glucose method. (mg/dL), Mean Baseline 169 176 168 Change at Week 30 +14 −5 −10 Difference from placebo (95% CI) −20 [−32, −7] −24 [−37, −12] In Combination with a Sulfonylurea (30 Weeks) Intent-to-Treat Population (N) 123 125 129 HbA 1c (%), Mean Baseline 8.7 8.5 8.6 Change at Week 30 +0.1 −0.5 −0.9 Difference from placebo (95% CI) −0.6 [−0.9, −0.3] −1.0 [−1.3, −0.7] Proportion Achieving HbA 1c <7% 10% 25% 36% Body Weight (kg), Mean Baseline 99.1 94.9 95.2 Change at Week 30 −0.8 −1.1 −1.6 Difference from placebo (95% CI) −0.3 [−1.1, 0.6] −0.9 [−1.7, −0.0] Fasting Plasma Glucose (mg/dL), Mean Baseline 194 180 178 Change at Week 30 +6 −5 −11 Difference from placebo (95% CI) −11 [−25, 3] −17 [−30, −3] In Combination with Metformin and a Sulfonylurea (30 Weeks) Intent-to-Treat Population (N) 247 245 241 HbA 1c (%), Mean Baseline 8.5 8.5 8.5 Change at Week 30 +0.1 −0.7 −0.9 Difference from placebo (95% CI) −0.8 [−1.0, −0.6] −1.0 [−1.2, −0.8] Proportion Achieving HbA 1c <7% 8% 25% 31% Body Weight (kg), Mean Baseline 99.1 96.9 98.4 Change at Week 30 −0.9 −1.6 −1.6 Difference from placebo (95% CI) −0.7 [−1.2, −0.2] −0.7 [−1.3, −0.2] Fasting Plasma Glucose (mg/dL), Mean Baseline 181 182 178 Change at Week 30 +13 −11 −12 Difference from placebo (95% CI) −24 [−33, −15] −25 [−34, −16] In Combination with a Thiazolidinedione or a Thiazolidinedione plus Metformin (16 Weeks) Intent-to-Treat Population (N) 112 Dose not studied 121 HbA 1c (%), Mean Baseline 7.9 Dose not studied 7.9 Change at Week 16 +0.1 Dose not studied −0.7 Difference from placebo (95% CI) Dose not studied −0.9 [−1.1, −0.7] Proportion Achieving HbA 1c <7% 15% Dose not studied 51% Body Weight (kg), Mean Baseline 96.8 Dose not studied 97.5 Change at Week 16 −0.0 Dose not studied −1.5 Difference from placebo (95% CI) Dose not studied −1.5 [−2.2, −0.7] Fasting Serum Glucose (mg/dL), Mean Baseline 159 Dose not studied 164 Change at Week 16 +4 Dose not studied −21 Difference from placebo (95% CI) Dose not studied −25 [−33, −16] BID = twice daily. HbA 1c The addition of BYETTA to a regimen of metformin, a sulfonylurea, or both, resulted in statistically significant reductions from baseline in HbA 1c compared with patients receiving placebo added to these agents in the three controlled trials (Table 8). In the 16-week trial of BYETTA add-on to thiazolidinediones, with or without metformin, BYETTA resulted in statistically significant reductions from baseline in HbA 1c compared with patients receiving placebo (Table 8). Postprandial Glucose Postprandial glucose was measured after a mixed meal tolerance test in 9.5% of patients participating in the 30-week add-on to metformin, add-on to sulfonylurea, and add-on to metformin in combination with sulfonylurea clinical trials. In this pooled subset of patients, BYETTA reduced postprandial plasma glucose concentrations in a dose-dependent manner. The mean (SD) change in 2-hour postprandial glucose concentration following administration of BYETTA at Week 30 relative to baseline was − 63 (65) mg/dL for 5 mcg BID (n=42), − 71 (73) mg/dL for 10 mcg BID (n=52), and +11 (69) mg/dL for placebo BID (n=44). 14.3 Combination with Insulin Glargine 30-Week Placebo-Controlled Trial A 30-week, double-blind, placebo-controlled trial was conducted to evaluate the efficacy and safety of BYETTA (n=137) versus placebo (n=122) when added to titrated insulin glargine, with or without metformin and/or thiazolidinedione, in patients with type 2 diabetes with inadequate glycemic control. All patients assigned to BYETTA initially received 5 mcg BID for 4 weeks. After 4 weeks, those patients assigned to BYETTA had their dose increased to 10 mcg BID. Patients assigned to placebo received placebo BID throughout the trial. BYETTA or placebo was injected subcutaneously before the morning and evening meals. Patients with an HbA1c ≤8.0% decreased their prestudy dose of insulin glargine by 20% and patients with an HbA1c ≥8.1% maintained their current dose of insulin glargine. Five weeks after initiating randomized treatment, insulin doses were titrated with guidance from the investigator toward predefined fasting glucose targets according to the dose titration algorithm provided in Table 9. The majority of patients (78%) were White, 10% were American Indian or Alaska Native, 9% were Black or African American, 3% were Asian, and 0.8% were of multiple origins. The primary endpoint was the change in HbA1c from baseline to Week 30. Compared to placebo, BYETTA 10 mcg BID resulted in statistically significant reductions in HbA1c from baseline at Week 30 (Table 9) in patients receiving titrated insulin glargine. Table 9: 30-Week Placebo-Controlled Trial of BYETTA Used in Combination with Insulin Glargine with or without Metformin and/or Thiazolidinediones Placebo BID + Titrated Insulin Glargine BYETTA 10 mcg BYETTA 5 mcg twice daily for 1 month followed by 10 mcg BID for 5 months for the 30-week trial. BID + Titrated Insulin Glargine Intent-to-Treat Population (N) 122 137 HbA 1c (%), Mean Baseline 8.5 8.3 Change at Week 30 Least squares means are based on a mixed model adjusting for treatment, pooled investigator, visit, baseline HbA 1c value, and treatment by visit, where subject is treated as a random effect. −1.0 −1.7 Difference from placebo (95% CI) −0.7 [−1.0, −0.5] p <0.01, treatment vs. placebo. Proportion Achieving HbA 1c <7% 29% 56% Body Weight (kg), Mean Baseline 93.8 95.4 Change at Week 30 Least squares means are based on a mixed model adjusting for treatment, pooled investigator, visit, baseline HbA 1c stratum, baseline value of the dependent variable (where applicable), and treatment by visit, where subject is treated as a random effect. 1.0 −1.8 Difference from placebo (95% CI) −2.7 [−3.7, −1.7] Fasting Serum Glucose Patients in both groups titrated insulin glargine dose to achieve optimal fasting glucose concentrations. (mg/dL), Mean Baseline 133 132 Change at Week 30 −16 −23 Difference from placebo (95% CI) −7 [−18, 3] BID = twice daily. Table 10: Dosing Algorithm for Titration of Insulin Glargine Adapted from Riddle et al. 2003. Fasting Plasma Glucose Values (mg/dL) Dose Change (U) <56 Value for at least 1 fasting plasma glucose measurement since the last assessment. − 4 56 to 72 − 2 73 to 99 Based on the average of fasting plasma glucose measurements taken over the prior 3 to 7 days. The increase in the total daily dose should not have exceeded more than 10 units per day or 10% of the current total daily dose, whichever was greater. 0 100 to 119 +2 120 to 139 +4 140 to 179 +6 ≥180 +8 Abbreviations: U = units. 30-Week Comparator-Controlled Noninferiority Trial A 30 week, open-label, active comparator-controlled, noninferiority study was conducted to evaluate the safety and efficacy of BYETTA (n=315) versus titrated insulin lispro (n=312) on a background of optimized basal insulin glargine and metformin in patients with type 2 diabetes with inadequate glycemic control. Following a 12-week basal insulin optimization (BIO) phase, subjects with an HbA 1c >7.0% entered a 30-week intervention phase and were randomized to add either BYETTA or insulin lispro to their existing regimen of insulin glargine and metformin. Insulin glargine was titrated to a target fasting plasma glucose of 72 to 100 mg/dL. All patients assigned to BYETTA initially received 5 mcg BID for four weeks. After four weeks, their dose was increased to 10 mcg BID. Patients in the BYETTA-treated arm with an HbA 1c ≤8.0% at the end of the BIO phase decreased their insulin glargine dose by at least 10%. All patients assigned to insulin lispro three times daily (TID) maintained their prior total daily insulin dose at baseline; however, the initial insulin lispro dose was ⅓ to ½ of the total daily insulin dose with the insulin glargine dose reduced accordingly. The insulin lispro dose was titrated based on preprandial glucose values. The majority of patients (87%) were White, 7% were American Indian or Alaska Native, 5% were Asian, and <1% were of Black or African American ethnicity. The primary endpoint was the change in HbA 1c from baseline to Week 30. Both BYETTA 10 mcg BID and titrated lispro provided a mean reduction in HbA 1c at Week 30 that met the pre-specified non-inferiority margin of 0.4%. Table 11: 30-Week Comparator-Controlled Trial of BYETTA used in Combination with Insulin Glargine and Metformin Titrated Insulin Lispro TID + Titrated Insulin Glargine BYETTA 10 mcg BYETTA 5 mcg BID for 1 month followed by 10 mcg BID for 5 months for the 30-week trial. BID + Titrated Insulin Glargine Intent-to-Treat Population (N) 312 315 HbA 1c (%), Mean Baseline 8.2 8.3 Change at Week 30 Least squares means are based on a mixed model adjusting for treatment, country, prior use of sulfonylurea (yes/no), visit, corresponding baseline, and treatment by visit interaction, where subject is treated as a random effect. Data at 30 weeks are available from 88% and 84% of the intent-to-treat subjects in the Lispro and BYETTA groups, respectively. −1.1 −1.1 Difference from Insulin Lispro (95% CI) −0.0 [−0.2, 0.1] Body Weight (kg), Mean Baseline 89.3 89.9 Change at Week 30 1.9 −2.6 Difference from Insulin Lispro (95% CI) −4.5 [−5.2, −3.9] Fasting Serum Glucose Patients titrated insulin glargine or insulin lispro dose to achieve prespecified target fasting and preprandial glucose concentrations. (mg/dL), Mean Baseline 126 130 Change at Week 30 5 −7 Difference from Insulin Lispro (95% CI) −12 [−19, −4] BID = twice daily. TID = three times daily.

Exenatide

SUBCUTANEOUS · Amneal Pharmaceuticals LLC

Label effective · version 17Retrieved · Nov 17, 2026 UTCFull label on DailyMed (dailymed.nlm.nih.gov)Indexed source record (api.fda.gov)
Read indexed warnings and label text

Boxed warning

This section was not supplied in the indexed record. Check the full source label.

Contraindications

4 CONTRAINDICATIONS Exenatide injection is contraindicated in patients with: A prior severe hypersensitivity reaction to exenatide or to any of the excipients in exenatide injection. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with exenatide injection [see Warnings and Precautions (5.7) ] . A history of drug-induced immune-mediated thrombocytopenia from exenatide products. Serious bleeding, which may be fatal, from drug-induced immune-mediated thrombocytopenia has been reported with exenatide use [see Warnings and Precautions (5.8) ]. History of severe hypersensitivity to exenatide or any of the excipients in exenatide injection. ( 4 ) History of drug-induced immune-mediated thrombocytopenia from exenatide products. ( 4 )

Indications and uses

1 INDICATIONS AND USAGE Exenatide injection is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Exenatide injection is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 , 14 ) Limitations of Use Co-administration with other exenatide-containing products is not recommended. ( 1 ) Limitations of Use Exenatide injection contains exenatide. Co-administration with other exenatide-containing products is not recommended.

Dosing and administration

2 DOSAGE AND ADMINISTRATION Inject subcutaneously within 60 minutes prior to morning and evening meals (or before the two main meals of the day, approximately 6 hours or more apart). ( 2.1 ) Initiate at 5 mcg per dose twice daily; increase to 10 mcg twice daily after 1 month based on clinical response. ( 2.1 ) 2.1 Recommended Dosing Initiate exenatide injection at 5 mcg administered subcutaneously twice daily at any time within the 60-minute period before the morning and evening meals (or before the two main meals of the day, approximately 6 hours or more apart). Do not administer after a meal. Based on clinical response, the dose of exenatide injection can be increased to 10 mcg twice daily which is recommended after 1 month of therapy, in order to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions (5.5) and Adverse Reactions (6.1) ] . Administer as a subcutaneous injection in the thigh, abdomen, or upper arm. Rotate injections sites with each dose. Do not use the same site for each injection. Inspect visually for particulate matter and discoloration. Only use exenatide injection if the solution appears clear, colorless and contains no particles. When using exenatide injection with insulin, administer as separate injections and never mix. It is acceptable to inject exenatide injection and insulin in the same body region, but the injections should not be adjacent to each other. If a dose is missed, resume the treatment regimen as prescribed with the next scheduled dose.

Warnings and precautions

5 WARNINGS AND PRECAUTIONS Acute Pancreatitis : Has been observed in patients treated with GLP-1 receptor agonists, including exenatide. Discontinue if pancreatitis is suspected. ( 5.1 ) Never share an exenatide injection pen between patients, even if the needle is changed. ( 5.2 ) Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin : Patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. Reduction in the dose of insulin secretagogues or insulin may be necessary. ( 5.3 ) Acute Kidney Injury Due to Volume Depletion : Monitor renal function in patients reporting adverse reactions that could lead to volume depletion. ( 5.4 ) Severe Gastrointestinal Adverse Reactions : Use has been associated with gastrointestinal adverse reactions, sometimes severe. Exenatide is not recommended in patients with severe gastroparesis. ( 5.5 ) Immunogenicity : Patients may develop antibodies to exenatide. If there is worsening glycemic control or failure to achieve target glycemic control, consider alternative antidiabetic therapy. ( 5.6 ) Hypersensitivity : Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue exenatide and promptly seek medical advice. ( 5.7 ) Drug-induced Immune-mediated Thrombocytopenia : Serious bleeding which may be fatal has been reported. Discontinue exenatide promptly and avoid re-exposure to exenatide. ( 5.8 ) Acute Gallbladder Disease: If cholelithiasis or cholecystitis are suspected, gallbladder studies are indicated. ( 5.9 ) Pulmonary Aspiration During General Anesthesia or Deep Sedation: Has been reported in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures. Instruct patients to inform healthcare providers of any planned surgeries or procedures. ( 5.10 ) 5.1 Acute Pancreatitis Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with glucagon-like peptide-1 (GLP-1) receptor agonists, including exenatide [see Adverse Reactions (6.2) ]. After initiation of exenatide, observe patients carefully for signs and symptoms of acute pancreatitis which may include persistent or severe abdominal pain (sometimes radiating to the back) and which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, discontinue exenatide and initiate appropriate management. 5.2 Never Share an Exenatide Injection Pen Between Patients Exenatide injection pens must never be shared between patients, even if the needle is changed. Pen-sharing poses a risk for transmission of blood-borne pathogens. 5.3 Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin Patients receiving exenatide in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia including severe hypoglycemia [see Adverse Reactions (6) and Drug Interactions (7) ] . The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia. 5.4 Acute Kidney Injury Due to Volume Depletion There have been post-marketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists, exenatide [see Adverse Reactions (6.2) ]. The majority of the reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea [see Adverse Reactions (6) ]. Monitor renal function in patients reporting adverse reactions to exenatide that could lead to volume depletion, especially during dosage initiation and escalation of exenatide. Exenatide is not recommended in patients with severe renal impairment (creatinine clearance <30 mL/min) or end-stage renal disease and should be used with caution in patients with renal transplantation [see Use in Specific Populations (8.6) ] . 5.5 Severe Gastrointestinal Adverse Reactions Use of GLP-1 receptor agonists, including exenatide, has been associated with gastrointestinal adverse reactions, sometimes severe [see Adverse Reactions (6) ]. Severe gastrointestinal adverse reactions have also been reported postmarketing with GLP-1 receptor agonists. Exenatide is not recommended in patients with severe gastroparesis. 5.6 Immunogenicity Patients may develop antibodies to exenatide following treatment with exenatide. Antibody levels were measured in 90% of subjects in the 30-week, 24-week, and 16-week placebo-controlled studies and the 30-week comparator-controlled study of exenatide. In 3%, 4%, 1% and 1% of these patients, respectively, antibody formation was associated with an attenuated glycemic response. If there is worsening glycemic control or failure to achieve targeted glycemic control, alternative antidiabetic therapy should be considered [see Adverse Reactions (6.1) ] . 5.7 Hypersensitivity There have been post-marketing reports of serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) in patients treated with exenatide. If a hypersensitivity reaction occurs, the patient should discontinue exenatide and other suspect medications and promptly seek medical advice. Inform and closely monitor patients with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist for allergic reactions, because it is unknown whether such patients will be predisposed to anaphylaxis with exenatide [see Adverse Reactions (6.2) ] . 5.8 Drug-Induced Thrombocytopenia Serious bleeding, which may be fatal, from drug-induced immune-mediated thrombocytopenia has been reported in the post-marketing setting with exenatide use. Drug-induced thrombocytopenia is an immune-mediated reaction, with exenatide-dependent anti-platelet antibodies. In the presence of exenatide, these antibodies cause platelet destruction. If drug-induced thrombocytopenia is suspected, discontinue exenatide immediately and do not re-expose the patient to exenatide [see Adverse Reactions (6.2) ] . 5.9 Acute Gallbladder Disease Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and post-marketing. In a clinical study with exenatide, 1.9% of exenatide-treated patients and 1.4% of placebo-treated patients reported an acute event of gallbladder disease, such as cholelithiasis or cholecystitis. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated. 5.10 Pulmonary Aspiration During General Anesthesia or Deep Sedation Exenatide delays gastric emptying [see Clinical Pharmacology (12.2) ] . There have been rare post-marketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations. Available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking exenatide, including whether modifying preoperative fasting recommendations or temporarily discontinuing exenatide could reduce the incidence of retained gastric contents. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking exenatide.

Drug interactions

7 DRUG INTERACTIONS Table 6: Clinically Relevant Interactions with Exenatide Concomitant Use of Insulin Secretagogues or Insulin Clinical Impact Exenatide promotes insulin release from pancreatic beta-cells in the presence of elevated glucose concentrations. The risk of hypoglycemia is increased when exenatide is used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin [see Warnings and Precautions (5.3) and Adverse Reactions (6) ] . Intervention When initiating exenatide, consider reducing the dose of concomitantly administered insulin secretagogue or insulin to reduce the risk of hypoglycemia. Warfarin Clinical Impact In a drug interaction study, exenatide did not have a significant effect on INR [see Clinical Pharmacology (12.3) ] . There have been post-marketing reports for exenatide of increased INR with concomitant use of warfarin, sometimes associated with bleeding [see Adverse Reactions (6.2) ] . Intervention In patients taking warfarin, the prothrombin time should be monitored more frequently after initiation or alteration of exenatide therapy. Once a stable prothrombin time has been documented, the prothrombin time can be monitored at the intervals recommended for patients taking warfarin. Orally Administered Drugs (e.g., acetaminophen) Clinical Impact Exenatide slows gastric emptying. Therefore, exenatide has the potential to reduce the rate of absorption of orally administered drugs [see Clinical Pharmacology (12.3) ]. Intervention Use caution when administering oral medications with exenatide where a slower rate of oral absorption may be clinically meaningful. For oral medications that are dependent on threshold concentrations for efficacy, such as contraceptives and antibiotics, patients should be advised to take those drugs at least 1 hour before exenatide injection. If such drugs are to be administered with food, patients should be advised to take them with a meal or snack when exenatide is not administered [see Clinical Pharmacology (12.3) ] . May impact absorption of orally administered medications. ( 7 ) Warfarin: Post-marketing reports of increased INR sometimes associated with bleeding. Monitor INR frequently until stable upon initiation or alteration of exenatide therapy. ( 7 )

Adverse reactions

6 ADVERSE REACTIONS The following serious adverse reactions are described below or elsewhere in the prescribing information: Acute Pancreatitis [see Warnings and Precautions (5.1) ] Never Share an Exenatide Pen Between Patients [see Warnings and Precautions (5.2) ] Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3) ] Acute Kidney Injury Due to Volume Depletion [see Warnings and Precautions (5.4) ] Severe Gastrointestinal Adverse Reactions [see Warnings and Precautions (5.5) ] Immunogenicity [see Warnings and Precautions (5.6) ] Hypersensitivity [see Warnings and Precautions (5.7) ] Drug-Induced Thrombocytopenia [see Warnings and Precautions (5.8) ] Acute Gallbladder Disease [see Warnings and Precautions (5.9) ] Pulmonary Aspiration During General Anesthesia or Deep Sedation [see Warnings and Precautions (5.10) ] Most common (≥ 5%) and occurring more frequently than placebo in clinical trials: nausea, hypoglycemia, vomiting, diarrhea, feeling jittery, dizziness, headache, dyspepsia, constipation, asthenia. Nausea usually decreases over time. ( 5.3 , 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals LLC at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Hypoglycemia Table 1 summarizes the incidence and rate of hypoglycemia with exenatide in six placebo-controlled clinical trials. Table 1: Incidence (%) and Rate of Hypoglycemia when Exenatide was used as Monotherapy or with Concomitant Antidiabetic Therapy in Six Placebo-Controlled Clinical Trials * Placebo BID Exenatide 5 mcg BID Exenatide 10 mcg BID Monotherapy (24 Weeks) N 77 77 78 % Overall 1.3% 5.2% 3.8% Rate (episodes/patient-year) 0.03 0.21 0.52 % Severe 0.0% 0.0% 0.0% With Metformin (30 Weeks) N 113 110 113 % Overall 5.3% 4.5% 5.3% Rate (episodes/patient-year) 0.12 0.13 0.12 % Severe 0.0% 0.0% 0.0% With a Sulfonylurea (30 Weeks) N 123 125 129 % Overall 3.3% 14.4% 35.7% Rate (episodes/patient-year) 0.07 0.64 1.61 % Severe 0.0% 0.0% 0.0% With Metformin and a Sulfonylurea (30 Weeks) N 247 245 241 % Overall 12.6% 19.2% 27.8% Rate (episodes/patient-year) 0.58 0.78 1.71 % Severe 0.0% 0.4% 0.0% With a Thiazolidinedione (16 Weeks) N 112 not evaluated 121 % Overall 7.1% not evaluated 10.7% Rate (episodes/patient-years) 0.56 not evaluated 0.98 % Severe 0.0% not evaluated 0.0% With Insulin Glargine with or without Metformin and/or Thiazolidinedione (30 Weeks) † N 122 not evaluated 137 % Overall 29.5% not evaluated 24.8% Rate (episodes/patient-years) 1.58 not evaluated 1.61 % Severe 0.8% not evaluated 0.0% * A hypoglycemic episode was recorded if a patient reported symptoms of hypoglycemia with or without a blood glucose value consistent with hypoglycemia. Severe hypoglycemia was defined as an event with symptoms consistent with hypoglycemia requiring the assistance of another person and associated with either a documented blood glucose value < 54 mg/dL or prompt recovery after treatment for hypoglycemia. † When exenatide was initiated in combination with insulin glargine, the dose of insulin glargine was decreased by 20% in patients with an HbA 1c ≤ 8.0% to minimize the risk of hypoglycemia. See Table 10 for insulin dose titration algorithm. N = number of Intent-to-Treat subjects in each treatment group. Immunogenicity Antibodies were assessed in 90% of subjects in the 30-week, 24-week, and 16-week studies of exenatide. In the 30-week controlled trials of exenatide add-on to metformin and/or sulfonylurea, antibodies were assessed at 2- to 6-week intervals. The mean antibody titer peaked at Week 6 and was reduced by 55% by Week 30. Three hundred and sixty patients (38%) had low titer antibodies (< 625) to exenatide at 30 weeks. The level of glycemic control (HbA 1c ) in these patients was generally comparable to that observed in the 534 patients (56%) without antibody titers. An additional 59 patients (6%) had higher titer antibodies (≥ 625) at 30 weeks. Of these patients, 32 (3% overall) had an attenuated glycemic response to exenatide; the remaining 27 (3% overall) had a glycemic response comparable to that of patients without antibodies. In the 16-week trial of exenatide add-on to thiazolidinediones, with or without metformin, 36 patients (31%) had low titer antibodies to exenatide at 16 weeks. The level of glycemic control in these patients was generally comparable to that observed in the 69 patients (60%) without antibody titer. An additional 10 patients (9%) had higher titer antibodies at 16 weeks. Of these patients, 4 (4% overall) had an attenuated glycemic response to exenatide; the remaining 6 (5% overall) had a glycemic response comparable to that of patients without antibodies. In the 24-week trial of exenatide used as monotherapy, 40 patients (28%) had low titer antibodies to exenatide at 24 weeks. The level of glycemic control in these patients was generally comparable to that observed in the 101 patients (70%) without antibody titers. An additional 3 patients (2%) had higher titer antibodies at 24 weeks. Of these patients, 1 (1% overall) had an attenuated glycemic response to exenatide; the remaining 2 (1% overall) had a glycemic response comparable to that of patients without antibodies. Antibodies to exenatide were not assessed in the 30-week placebo-controlled trial of exenatide used in combination with insulin glargine. In the 30-week comparator-controlled trial of exenatide used in combination with insulin glargine and metformin, 60 patients (20%) had low titer antibodies to exenatide at 30 weeks. The level of glycemic control in these patients was generally comparable to that observed in the 234 patients (77%) without antibody titers. An additional 10 patients (3%) had higher titer antibodies at 30 weeks. Of these patients, 2 (1% overall) had an attenuated glycemic response to exenatide; the remaining 8 (3% overall) had a glycemic response comparable to that of patients without antibodies. Two hundred and ten patients with antibodies to exenatide in the exenatide clinical trials were tested for the presence of cross-reactive antibodies to GLP-1 and/or glucagon. No treatment-emergent cross-reactive antibodies were observed across the range of titers. Other Adverse Reactions Monotherapy For the 24-week placebo-controlled study of exenatide used as a monotherapy, Table 2 summarizes adverse reactions (excluding hypoglycemia) occurring with an incidence ≥ 2% and occurring more frequently in exenatide-treated patients compared with placebo-treated patients. Table 2: Treatment-Emergent Adverse Reactions ≥ 2% Incidence with Exenatide used as Monotherapy (excluding Hypoglycemia) * Monotherapy Placebo BID N=77 % All Exenatide BID N=155 % Nausea 0 8 Vomiting 0 4 Dyspepsia 0 3 * In a 24-week placebo-controlled trial. BID = twice daily. Adverse reactions reported in ≥ 1.0% to < 2.0% of patients receiving exenatide and reported more frequently than with placebo included decreased appetite, diarrhea and dizziness. The most frequently reported adverse reaction associated with exenatide, nausea, occurred in a dose-dependent fashion. Two of the 155 patients treated with exenatide withdrew due to adverse reactions of headache and nausea. No placebo-treated patients withdrew due to adverse reactions. Cholelithiasis and cholecystitis In a clinical study with exenatide, 1.9% of exenatide-treated patients and 1.4% of placebo-treated patients reported an acute event of gallbladder disease, such as cholelithiasis or cholecystitis. Combination Therapy Add-On to Metformin and/or Sulfonylurea In the three 30-week controlled trials of exenatide add-on to metformin and/or sulfonylurea, adverse reactions (excluding hypoglycemia) with an incidence ≥ 2% and occurring more frequently in exenatide-treated patients compared with placebo-treated patients are summarized in Table 3. Table 3: Treatment-Emergent Adverse Reactions ≥ 2% Incidence and Greater Incidence with Exenatide Treatment used with Metformin and/or a Sulfonylurea (excluding Hypoglycemia) * Placebo BID N=483 % All Exenatide BID N=963 % Nausea 18 44 Vomiting 4 13 Diarrhea 6 13 Feeling Jittery 4 9 Dizziness 6 9 Headache 6 9 Dyspepsia 3 6 Asthenia 2 4 Gastroesophageal Reflux Disease 1 3 Hyperhidrosis 1 3 * In three 30-week placebo-controlled clinical trials. BID = twice daily. Adverse reactions reported in ≥ 1.0% to < 2.0% of patients receiving exenatide and reported more frequently than with placebo included decreased appetite. Nausea was the most frequently reported adverse reaction and occurred in a dose-dependent fashion. With continued therapy, the frequency and severity decreased over time in most of the patients who initially experienced nausea. Patients in the long-term uncontrolled open-label extension studies at 52 weeks reported no new types of adverse reactions than those observed in the 30-week controlled trials. The most common adverse reactions leading to withdrawal for exenatide-treated patients were nausea (3% of patients) and vomiting (1%). For placebo-treated patients, < 1% withdrew due to nausea and none due to vomiting. Add-On to Thiazolidinedione with or without Metformin For the 16-week placebo-controlled study of exenatide add-on to a thiazolidinedione, with or without metformin, Table 4 summarizes the adverse reactions (excluding hypoglycemia) with an incidence of ≥ 2% and occurring more frequently in exenatide-treated patients compared with placebo-treated patients. Table 4: Treatment-Emergent Adverse Reactions ≥ 2% Incidence with Exenatide used with a Thiazolidinedione (TZD), with or without Metformin (MET) (excluding Hypoglycemia) * With a TZD or TZD/MET Placebo N=112 % All Exenatide BID N=121 % Nausea 15 40 Vomiting 1 13 Dyspepsia 1 7 Diarrhea 3 6 Gastroesophageal Reflux Disease 0 3 * In a 16-week placebo-controlled clinical trial. BID = twice daily. Adverse reactions reported in ≥ 1.0% to < 2.0% of patients receiving exenatide and reported more frequently than with placebo included decreased appetite. Chills (n=4) and injection-site reactions (n=2) occurred only in exenatide-treated patients. The two patients who reported an injection-site reaction had high titers of antibodies to exenatide. Two serious adverse events (chest pain and chronic hypersensitivity pneumonitis) were reported in the exenatide arm. No serious adverse events were reported in the placebo arm. The most common adverse reactions leading to withdrawal for exenatide-treated patients were nausea (9%) and vomiting (5%). For placebo-treated patients, < 1% withdrew due to nausea. Add-On to Insulin Glargine with or without Metformin and/or Thiazolidinedione (Placebo-Controlled) For the 30-week placebo-controlled study of exenatide as add-on to insulin glargine with or without oral antihyperglycemic medications, Table 5 summarizes adverse reactions (excluding hypoglycemia) occurring with an incidence ≥ 2% and occurring more frequently in exenatide-treated patients compared with placebo-treated patients. Table 5: Treatment-Emergent Adverse Reactions ≥ 2% Incidence with Exenatide used with Insulin Glargine with or without Oral Antihyperglycemic Medications (excluding Hypoglycemia) * With Insulin Glargine Placebo N=122 % All Exenatide BID N=137 % Nausea 8 41 Vomiting 4 18 Diarrhea 8 18 Headache 4 14 Constipation 2 10 Dyspepsia 2 7 Asthenia 1 5 Abdominal Distension 1 4 Decreased Appetite 0 3 Flatulence 1 2 Gastroesophageal Reflux Disease 1 2 * In a 30-week placebo-controlled clinical trial. BID = twice daily. The most frequently reported adverse reactions leading to withdrawal for exenatide-treated patients were nausea (5.1%) and vomiting (2.9%). No placebo-treated patients withdrew due to nausea or vomiting. 6.2 Post-marketing Experience The following additional adverse reactions have been reported during post-approval use of exenatide or other formulations of exenatide. Because these events are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood : Drug-induced thrombocytopenia. Drug Interactions: International normalized ratio (INR) increased with concomitant warfarin use sometimes associated with bleeding [see Drug Interactions (7) ] . Gastrointestinal: Nausea, vomiting and/or diarrhea resulting in dehydration; abdominal distension, abdominal pain, eructation, constipation, flatulence, ileus, acute pancreatitis, hemorrhagic and necrotizing pancreatitis sometimes resulting in death, intestinal obstruction, severe constipation including fecal impaction. Hepatobiliary: Cholecystitis, cholelithiasis requiring cholecystectomy. Hypersensitivity: Injection-site reactions, generalized pruritus and/or urticaria, macular or papular rash, angioedema, anaphylactic reaction. Neurologic: Dysgeusia; somnolence, dysesthesia. Pulmonary: Pulmonary aspiration has occurred in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation. Renal: Altered renal function, including increased serum creatinine, renal impairment, worsened chronic renal failure or acute renal failure (sometimes requiring hemodialysis), kidney transplant and kidney transplant dysfunction. Skin and Subcutaneous Tissue: Alopecia.

Clinical studies

14 CLINICAL STUDIES Exenatide has been studied as monotherapy and in combination with metformin, a sulfonylurea, a thiazolidinedione, a combination of metformin and a sulfonylurea, a combination of metformin and a thiazolidinedione, or in combination with insulin glargine with or without metformin and/or thiazolidinedione. 14.1 Monotherapy In a randomized, double-blind, placebo-controlled trial of 24 weeks duration, exenatide 5 mcg BID (n=77), exenatide 10 mcg BID (n=78), or placebo BID (n=77) was used as monotherapy in patients with entry HbA 1c ranging from 6.5% to 10%. All patients assigned to exenatide initially received 5 mcg BID for 4 weeks. After 4 weeks, those patients either continued to receive exenatide 5 mcg BID or had their dose increased to 10 mcg BID. Patients assigned to placebo received placebo BID throughout the trial. Exenatide or placebo was injected subcutaneously before the morning and evening meals. The majority of patients (68%) were White, 26% were West Asian, 3% were Hispanic or Latino ethnicity, 3% were Black or African American and 0.4% were of East Asian ethnicity. The primary endpoint was the change in HbA 1c from baseline to Week 24 (or the last value at time of early discontinuation). Compared to placebo, exenatide 5 mcg BID and 10 mcg BID resulted in statistically significant reductions in HbA 1c from baseline at Week 24 (Table 7). Table 7: Results of 24-Week Placebo-Controlled Trial of Exenatide used as Monotherapy Placebo BID Exenatide 5 mcg BID Exenatide 10 mcg * BID Intent-to-Treat Population (N) 77 77 78 HbA 1c (%), Mean Baseline 7.8 7.9 7.8 Change at Week 24 † -0.2 -0.7 -0.9 Difference from placebo † (95% CI) -0.5 [-0.9, -0.2] ‡ -0.7 [-1.0, -0.3] Proportion Achieving HbA 1c < 7% 38% 48% 53% Body Weight (kg), Mean Baseline 86.1 85.1 86.2 Change at Week 24 † -1.5 -2.7 -2.9 Difference from placebo † (95% CI) -1.3 [-2.3, -0.2] -1.5 [-2.5, -0.4] Fasting Serum Glucose § (mg/dL), Mean Baseline 159 166 155 Change at Week 24 † -5 -17 -19 Difference from placebo † (95% CI) -12 [-23.2, -1.3] -14 [-24.5, -2.5] * Exenatide 5 mcg twice daily (BID) for 1 month followed by 10 mcg BID for 5 months before the morning and evening meals. † Least squares means are adjusted for screening HbA 1c strata and baseline value of the dependent variable. ‡ p < 0.01, treatment vs. placebo. § Measured using the hexokinase-based glucose method. BID = twice daily. On average, there were no adverse effects of exenatide on blood pressure or lipids. 14.2 Combination Therapy with Oral Antihyperglycemic Medicines Three 30-week, double-blind, placebo-controlled trials were conducted to evaluate the safety and efficacy of exenatide in patients with type 2 diabetes whose glycemic control was inadequate with metformin alone, a sulfonylurea alone, or metformin in combination with a sulfonylurea. In addition, a 16-week, placebo-controlled trial was conducted where exenatide was added to existing thiazolidinedione (pioglitazone or rosiglitazone) treatment, with or without metformin, in patients with type 2 diabetes with inadequate glycemic control. In the 30-week trials, after a 4-week placebo lead-in period, patients were randomly assigned to receive exenatide 5 mcg BID, exenatide 10 mcg BID, or placebo BID before the morning and evening meals, in addition to their existing oral antidiabetic agent. All patients assigned to exenatide initially received 5 mcg BID for 4 weeks. After 4 weeks, those patients either continued to receive exenatide 5 mcg BID or had their dose increased to 10 mcg BID. Patients assigned to placebo received placebo BID throughout the study. A total of 1,446 patients were randomized in the three 30-week trials: 991 (69%) were White, 224 (16%) were Hispanic or Latino and 174 (12%) were of Black of African American ethnicity. Mean HbA 1c values at baseline for the trials ranged from 8.2% to 8.7%. In the placebo-controlled trial of 16 weeks duration, exenatide (n=121) or placebo (n=112) was added to existing thiazolidinedione (pioglitazone or rosiglitazone) treatment, with or without metformin. Randomization to exenatide or placebo was stratified based on whether the patients were receiving metformin. Exenatide treatment was initiated at a dose of 5 mcg BID for 4 weeks then increased to 10 mcg BID for 12 more weeks. Patients assigned to placebo received placebo BID throughout the study. Exenatide or placebo was injected subcutaneously before the morning and evening meals. In this trial, 79% of patients were taking a thiazolidinedione and metformin and 21% were taking a thiazolidinedione alone. The majority of patients (84%) were White, 8% were Hispanic or Latino ethnicity and 3% were of Black or African American ethnicity. The mean baseline HbA 1c values were 7.9% for exenatide and placebo. The primary endpoint in each study was the mean change in HbA 1c from baseline to study end (or early discontinuation). Table 8 summarizes the study results for the 30- and 16-week clinical trials. Table 8: Results of 30-Week and 16-Week Placebo-Controlled Trials of Exenatide used in Combination with Oral Antidiabetic Agents Placebo BID Exenatide 5 mcg BID Exenatide 10 mcg * BID In Combination with Metformin (30 Weeks) Intent-to-Treat Population (N) 113 110 113 HbA 1c (%), Mean Baseline 8.2 8.3 8.2 Change at Week 30 † -0.0 -0.5 -0.9 Difference from placebo † (95% CI) -0.5 [-0.7, -0.2] ‡ -0.9 [-1.1, -0.6] ‡ Proportion Achieving HbA 1c < 7% 12% 32% 40% Body Weight (kg), Mean Baseline 99.9 100.0 100.9 Change at Week 30 † -0.2 -1.3 -2.6 Difference from placebo † (95% CI) -1.1 [-2.2, -0.0] -2.4 [-3.5, -1.3] Fasting Plasma Glucose § (mg/dL), Mean Baseline 169 176 168 Change at Week 30 † +14 -5 -10 Difference from placebo † (95% CI) -20 [-32, -7] -24 [-37, -12] In Combination with a Sulfonylurea (30 Weeks) Intent-to-Treat Population (N) 123 125 129 HbA 1c (%), Mean Baseline 8.7 8.5 8.6 Change at Week 30 † +0.1 -0.5 -0.9 Difference from placebo † (95% CI) -0.6 [-0.9, -0.3] ‡ -1.0 [-1.3, -0.7] ‡ Proportion Achieving HbA 1c < 7% 10% 25% 36% Body Weight (kg), Mean Baseline 99.1 94.9 95.2 Change at Week 30 † -0.8 -1.1 -1.6 Difference from placebo † (95% CI) -0.3 [-1.1, 0.6] -0.9 [-1.7, -0.0] Fasting Plasma Glucose § (mg/dL), Mean Baseline 194 180 178 Change at Week 30 † +6 -5 -11 Difference from placebo † (95% CI) -11 [-25, 3] -17 [-30, -3] In Combination with Metformin and a Sulfonylurea (30 Weeks) Intent-to-Treat Population (N) 247 245 241 HbA 1c (%), Mean Baseline 8.5 8.5 8.5 Change at Week 30 † +0.1 -0.7 -0.9 Difference from placebo † (95% CI) -0.8 [-1.0, -0.6] ‡ -1.0 [-1.2, -0.8] ‡ Proportion Achieving HbA 1c < 7% 8% 25% 31% Body Weight (kg), Mean Baseline 99.1 96.9 98.4 Change at Week 30 † -0.9 -1.6 -1.6 Difference from placebo † (95% CI) -0.7 [-1.2, -0.2] -0.7 [-1.3, -0.2] Fasting Plasma Glucose § (mg/dL), Mean Baseline 181 182 178 Change at Week 30 † +13 -11 -12 Difference from placebo † (95% CI) -24 [-33, -15] -25 [-34, -16] In Combination with a Thiazolidinedione or a Thiazolidinedione plus Metformin (16 Weeks) Intent-to-Treat Population (N) 112 Dose not studied 121 HbA 1c (%), Mean Baseline 7.9 Dose not studied 7.9 Change at Week 16 † +0.1 Dose not studied -0.7 Difference from placebo † (95% CI) Dose not studied -0.9 [-1.1, -0.7] ‡ Proportion Achieving HbA 1c < 7% 15% Dose not studied 51% Body Weight (kg), Mean Baseline 96.8 Dose not studied 97.5 Change at Week 16 † -0.0 Dose not studied -1.5 Difference from placebo † (95% CI) Dose not studied -1.5 [-2.2, -0.7] Fasting Serum Glucose § (mg/dL), Mean Baseline 159 Dose not studied 164 Change at Week 16 † +4 Dose not studied -21 Difference from placebo † (95% CI) Dose not studied -25 [-33, -16] * Exenatide 5 mcg twice daily for 1 month followed by 10 mcg BID for 6 months for the 30-week trials or 10 mcg BID for 3 months in the 16-week trial before the morning and evening meals. † Least squares means are adjusted for baseline HbA 1c strata or value, investigator site, baseline value of the dependent variable (if applicable) and background antihyperglycemic therapy (if applicable). ‡ p < 0.01, treatment vs. placebo. § Measured using the hexokinase-based glucose method. BID = twice daily. HbA 1c The addition of exenatide to a regimen of metformin, a sulfonylurea, or both, resulted in statistically significant reductions from baseline in HbA 1c compared with patients receiving placebo added to these agents in the three controlled trials (Table 8). In the 16-week trial of exenatide add-on to thiazolidinediones, with or without metformin, exenatide resulted in statistically significant reductions from baseline in HbA 1c compared with patients receiving placebo (Table 8). Postprandial Glucose Postprandial glucose was measured after a mixed meal tolerance test in 9.5% of patients participating in the 30-week add-on to metformin, add-on to sulfonylurea, and add-on to metformin in combination with sulfonylurea clinical trials. In this pooled subset of patients, exenatide reduced postprandial plasma glucose concentrations in a dose-dependent manner. The mean (SD) change in 2-hour postprandial glucose concentration following administration of exenatide at Week 30 relative to baseline was −63 (65) mg/dL for 5 mcg BID (n=42), −71 (73) mg/dL for 10 mcg BID (n=52) and +11 (69) mg/dL for placebo BID (n=44). 14.3 Combination with Insulin Glargine 30-Week Placebo-Controlled Trial A 30-week, double-blind, placebo-controlled trial was conducted to evaluate the efficacy and safety of exenatide (n=137) versus placebo (n=122) when added to titrated insulin glargine, with or without metformin and/or thiazolidinedione, in patients with type 2 diabetes with inadequate glycemic control. All patients assigned to exenatide initially received 5 mcg BID for 4 weeks. After 4 weeks, those patients assigned to exenatide had their dose increased to 10 mcg BID. Patients assigned to placebo received placebo BID throughout the trial. Exenatide or placebo was injected subcutaneously before the morning and evening meals. Patients with an HbA 1c ≤ 8.0% decreased their pre-study dose of insulin glargine by 20% and patients with an HbA 1c ≥ 8.1% maintained their current dose of insulin glargine. Five weeks after initiating randomized treatment, insulin doses were titrated with guidance from the investigator toward predefined fasting glucose targets according to the dose titration algorithm provided in Table 9. The majority of patients (78%) were White, 10% were American Indian or Alaska Native, 9% were Black or African American, 3% were Asian, and 0.8% were of multiple origins. The primary endpoint was the change in HbA 1c from baseline to Week 30. Compared to placebo, exenatide 10 mcg BID resulted in statistically significant reductions in HbA 1c from baseline at Week 30 (Table 9) in patients receiving titrated insulin glargine. Table 9: 30-Week Placebo-Controlled Trial of Exenatide Used in Combination with Insulin Glargine with or without Metformin and/or Thiazolidinediones Placebo BID + Titrated Insulin Glargine Exenatide 10 mcg * BID + Titrated Insulin Glargine Intent-to-Treat Population (N) 122 137 HbA 1c (%), Mean Baseline 8.5 8.3 Change at Week 30 † -1.0 -1.7 Difference from placebo † (95% CI) -0.7 [-1.0, -0.5] ¶ Proportion Achieving HbA 1c < 7% 29% 56% Body Weight (kg), Mean Baseline 93.8 95.4 Change at Week 30 ‡ 1.0 -1.8 Difference from placebo ‡ (95% CI) -2.7 [-3.7, -1.7] ¶ Fasting Serum Glucose § (mg/dL), Mean Baseline 133 132 Change at Week 30 ‡ -16 -23 Difference from placebo ‡ (95% CI) -7 [-18, 3] * Exenatide 5 mcg twice daily for 1 month followed by 10 mcg BID for 5 months for the 30-week trial. † Least squares means are based on a mixed model adjusting for treatment, pooled investigator, visit, baseline HbA 1c value and treatment by visit, where subject is treated as a random effect. ‡ Least squares means are based on a mixed model adjusting for treatment, pooled investigator, visit, baseline HbA 1c stratum, baseline value of the dependent variable (where applicable) and treatment by visit, where subject is treated as a random effect. § Patients in both groups titrated insulin glargine dose to achieve optimal fasting glucose concentrations. ¶ p < 0.01, treatment vs. placebo. BID = twice daily. Table 10: Dosing Algorithm for Titration of Insulin Glargine * Fasting Plasma Glucose Values (mg/dL) Dose Change (U) < 56 † -4 56 to 72 † -2 73 to 99 ‡ 0 100 to 119 ‡ +2 120 to 139 ‡ +4 140 to 179 ‡ +6 ≥ 180 ‡ +8 Abbreviations: U = units. * Adapted from Riddle et al. 2003. † Value for at least 1 fasting plasma glucose measurement since the last assessment. ‡ Based on the average of fasting plasma glucose measurements taken over the prior 3 to 7 days. The increase in the total daily dose should not have exceeded more than 10 units per day or 10% of the current total daily dose, whichever was greater. 30-Week Comparator-Controlled Noninferiority Trial A 30 week, open-label, active comparator-controlled, noninferiority study was conducted to evaluate the safety and efficacy of exenatide (n=315) versus titrated insulin lispro (n=312) on a background of optimized basal insulin glargine and metformin in patients with type 2 diabetes with inadequate glycemic control. Following a 12-week basal insulin optimization (BIO) phase, subjects with an HbA 1c > 7.0% entered a 30-week intervention phase and were randomized to add either exenatide or insulin lispro to their existing regimen of insulin glargine and metformin. Insulin glargine was titrated to a target fasting plasma glucose of 72 to 100 mg/dL. All patients assigned to exenatide initially received 5 mcg BID for four weeks. After four weeks, their dose was increased to 10 mcg BID. Patients in the exenatide-treated arm with an HbA 1c ≤ 8.0% at the end of the BIO phase decreased their insulin glargine dose by at least 10%. All patients assigned to insulin lispro three times daily (TID) maintained their prior total daily insulin dose at baseline; however, the initial insulin lispro dose was ⅓ to 1/2 ; of the total daily insulin dose with the insulin glargine dose reduced accordingly. The insulin lispro dose was titrated based on preprandial glucose values. The majority of patients (87%) were White, 7% were American Indian or Alaska Native, 5% were Asian, and < 1% were of Black or African American ethnicity. The primary endpoint was the change in HbA 1c from baseline to Week 30. Both exenatide 10 mcg BID and titrated lispro provided a mean reduction in HbA 1c at Week 30 that met the pre-specified non-inferiority margin of 0.4%. Table 11: 30-Week Comparator-Controlled Trial of Exenatide used in Combination with Insulin Glargine and Metformin Titrated Insulin Lispro TID + Titrated Insulin Glargine Exenatide 10 mcg * BID + Titrated Insulin Glargine Intent-to-Treat Population (N) 312 315 HbA 1c (%), Mean Baseline 8.2 8.3 Change at Week 30 † # −1.1 −1.1 Difference from Insulin Lispro † # (95% CI) −0.0 [−0.2, 0.1] Body Weight (kg), Mean Baseline 89.3 89.9 Change at Week 30 † # 1.9 −2.6 Difference from Insulin Lispro † # (95% CI) −4.5 [−5.2, −3.9] Fasting Serum Glucose ‡ (mg/dL), Mean Baseline 126 130 Change at Week 30 † # 5 −7 Difference from Insulin Lispro † # (95% CI) −12 [−19, −4] * Exenatide 5 mcg BID for 1 month followed by 10 mcg BID for 5 months for the 30-week trial. † Least squares means are based on a mixed model adjusting for treatment, country, prior use of sulfonylurea (yes/no), visit, corresponding baseline, and treatment by visit interaction, where subject is treated as a random effect. # Data at 30 weeks are available from 88% and 84% of the intent-to-treat subjects in the Lispro and Exenatide groups, respectively. ‡ Patients titrated insulin glargine or insulin lispro dose to achieve prespecified target fasting and preprandial glucose concentrations. BID = twice daily. TID = three times daily.

Source: submitted product labeling via openFDA. A listing does not establish FDA approval and may differ from current approved labeling. Read the current prescribing information and consult a clinician.
Tolerability

Side effects reported in the trial

Reported adverse events and treatment discontinuation from the cited trial. These figures do not predict an individual response.

Discontinued for side effects

3.9% (accessdata.fda.gov/drugsatfda_docs/label/2024/209210s024lbl.pdf) (3.9% discontinued for adverse reactions · Bydureon BCise FDA label (2 mg, type 2 diabetes))

Reported as 3.9% discontinued for adverse reactions. The share of trial participants who stopped treatment because of adverse events. This does not measure all side effects or all reasons for stopping.

Had nausea

8.2% (accessdata.fda.gov/drugsatfda_docs/label/2024/209210s024lbl.pdf) (Nausea in the drug arm · Bydureon BCise FDA label (2 mg, type 2 diabetes))

The share of participants who reported nausea in this trial. Severity and duration are not captured by this percentage.

Nausea (8%) and injection-site nodules (11%) were the most common reactions; GI burden is markedly lower than the newer high-dose agents.

From Bydureon BCise FDA label (2 mg, type 2 diabetes) (from the FDA label adverse-reactions table (DURATION-1 does not cleanly report AE discontinuation); a diabetes population). Tolerability figures come from each drug's own trial (different doses, durations, and populations), so compare them as a guide, not a head-to-head. Source (accessdata.fda.gov).

Safety signals

Beyond the US label

Regulators' safety notices beside the US label, each cited and dated. Where it matters, each says whether the label itself mentions it yet.

Before surgery: risk of pulmonary aspiration

In November 2024 the FDA added a class-wide warning to every GLP-1 label. Because these drugs slow stomach emptying, food can remain in the stomach before a procedure and be inhaled into the lungs (aspiration) during general anesthesia or deep sedation, even after normal fasting. Tell your care team you take a GLP-1 well before any planned surgery or sedation.

FDA (class-wide label update) (secure.medicalletter.org) · as of Nov 5, 2024

Eyes: FDA requires a warning about sudden vision loss (NAION)

On November 9, 2026 the FDA said it is "requiring application holders for all GLP-1 RA medications to add information to the Warnings and Precautions section of labeling about the potential increased risk of NAION" (non-arteritic anterior ischemic optic neuropathy), which it describes as "a rare condition that can result in acute, painless, decreased vision in one eye, including permanent vision loss." Its analysis of 126 randomized trials found 6.4 NAION cases per 100,000 person-years on a GLP-1, against 3.8 on placebo or another glucose-lowering medicine. Its list names every GLP-1 sold in the US, from Ozempic, Wegovy, Mounjaro and Zepbound to Foundayo. FDA's advice: "Patients should contact their health care professional right away if they have any of these symptoms." None of the current US labels of Byetta, Wegovy, Rybelsus/Ozempic tablets, Trulicity, Saxenda, Victoza, Mounjaro, Zepbound, Ozempic and Foundayo mentions NAION; every new revision is searched in full within a day of its publication.

FDA Drug Safety Communication, November 9, 2026 (fda.gov) · as of Nov 9, 2026

Evidence

Clinical trials

332 of 381 registered studies indexed. Showing up to 12 records: posted results first, then late-phase trials. Registry counts are not a measure of evidence quality.

  • Primary outcome: Primary Efficacy Outcome MACE Events

    Selected primary outcome

    Results · Nov 17, 2026 UTC

    Primary Efficacy Outcome MACE Events

    Count of participants · Participants · Time to first event. Information collected during study period (anticipated to be up to 7.5 years).

    Analysis population: ITT population: all patients consented and randomized in the study without a major GCP violation. ITT population is analyzed as randomized.

    Number of patients who had a MACE event

    Placebo
    905 Participants (clinicaltrials.gov/study/NCT01144338)

    Overall outcome: 7396 Participants (clinicaltrials.gov/study/NCT01144338) analyzed

    Exenatide Once Weekly
    839 Participants (clinicaltrials.gov/study/NCT01144338)

    Overall outcome: 7356 Participants (clinicaltrials.gov/study/NCT01144338) analyzed

    Outcome definition & treatment groups

    The primary efficacy outcome variable is defined as the composite endpoint of cardiovascular death, nonfatal MI, or nonfatal stroke. The number of participants who had an event is reported in the results. The primary efficacy endpoint is the same as the primary safety endpoint, and the statistical analysis tests the superiority of exenatide against the placebo.

    Placebo: Matching placebo subcutaneous injections

    Exenatide Once Weekly: Exenatide 2mg once weekly subcutaneous injections

    One of 2 registered primary outcomes, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 30

    Selected primary outcome

    Results · Oct 22, 2026 UTC

    Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 30

    Least-squares mean · percent of hemoglobin · Baseline, 30 weeks

    Analysis population: Participants analyzed for this endpoint included the per protocol population, 247 and 263, respectively.

    Exenatide (BET)
    -1.13 percent of hemoglobin (clinicaltrials.gov/study/NCT00960661)

    Standard Error: 0.053 (clinicaltrials.gov)

    Overall outcome: 247 Participants (clinicaltrials.gov/study/NCT00960661) analyzed

    Insulin Lispro (BBT)
    -1.10 percent of hemoglobin (clinicaltrials.gov/study/NCT00960661)

    Standard Error: 0.051 (clinicaltrials.gov)

    Overall outcome: 263 Participants (clinicaltrials.gov/study/NCT00960661) analyzed

    Outcome definition & treatment groups

    Change in HbA1c from baseline following 30 weeks of therapy (i.e. HbA1c at week 30 minus HbA1c at baseline).

    Exenatide (BET): Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET)

    Insulin Lispro (BBT): Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT)

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Has results
    Primary outcome: Number of Patients With Treatment Failure

    Selected primary outcome

    Results · Oct 26, 2026 UTC

    Number of Patients With Treatment Failure

    Number · number of patients · Baseline to end of Period II (up to 4.5 years)

    Analysis population: ITT Efficacy Population: Enrolled patients with a baseline and at least one post-baseline measurement of HbA1c in Study Period II (including only Study Period II); patients analyzed according to treatment as randomized.

    Number of patients with treatment failure

    Exen + Met
    203 number of patients (clinicaltrials.gov/study/NCT00359762)

    Overall outcome: 490 Participants (clinicaltrials.gov/study/NCT00359762) analyzed

    Glim + Met
    262 number of patients (clinicaltrials.gov/study/NCT00359762)

    Overall outcome: 487 Participants (clinicaltrials.gov/study/NCT00359762) analyzed

    Number of patients censored

    Exen + Met
    287 number of patients (clinicaltrials.gov/study/NCT00359762)

    Overall outcome: 490 Participants (clinicaltrials.gov/study/NCT00359762) analyzed

    Glim + Met
    225 number of patients (clinicaltrials.gov/study/NCT00359762)

    Overall outcome: 487 Participants (clinicaltrials.gov/study/NCT00359762) analyzed

    Outcome definition & treatment groups

    Treatment failure is defined as one of the following:1. HbA1c exceeding 9% at any visit after the initial 3 months of treatment (i.e., earliest at Month 6), on the maximally tolerated dose of antidiabetic agents. 2. HbA1c exceeding 7% at 2 consecutive visits 3 months apart, after the initial 6 months of treatment (i.e., earliest at Month 9), on the maximally tolerated dose of antidiabetic agents.

    Exen + Met: Exenatide 10 mcg twice daily subcutaneously injected (5 mcg exenatide per dose for first 4 weeks followed by 10 mcg exenatide per dose for the remainder of period II) and daily oral Metformin

    Glim + Met: Glimepiride one 1 mg tablet daily with subsequent titration every 4 weeks to maximally-tolerated dose for the remainder of Period II and daily oral Metformin

    One of 2 registered primary outcomes, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Change in HbA1c From Baseline to Week 28

    Selected primary outcome

    Results · Oct 22, 2026 UTC

    Change in HbA1c From Baseline to Week 28

    Least-squares mean · % HbA1c · Baseline to Week 28

    Analysis population: The ITT analysis set included all randomized patients who received at least 1 dose of study medication and had at least 1 post-baseline HbA1c assessment.

    Dapagliflozin + Placebo
    -1.39 % HbA1c (clinicaltrials.gov/study/NCT02229396)

    95% Confidence Interval: -1.57 to -1.21 (clinicaltrials.gov)

    Overall outcome: 230 Participants (clinicaltrials.gov/study/NCT02229396) analyzed

    Exenatide + Dapagliflozin
    -1.98 % HbA1c (clinicaltrials.gov/study/NCT02229396)

    95% Confidence Interval: -2.16 to -1.79 (clinicaltrials.gov)

    Overall outcome: 228 Participants (clinicaltrials.gov/study/NCT02229396) analyzed

    Exenatide + Placebo
    -1.60 % HbA1c (clinicaltrials.gov/study/NCT02229396)

    95% Confidence Interval: -1.79 to -1.41 (clinicaltrials.gov)

    Overall outcome: 227 Participants (clinicaltrials.gov/study/NCT02229396) analyzed

    Outcome definition & treatment groups

    To compare the change from baseline to Week 28 in HbA1c between exenatide once weekly (EQW) 2 mg and dapagliflozin 10 mg administered simultaneously compared to EQW 2 mg alone and dapagliflozin 10 mg alone.

    Dapagliflozin + Placebo: Dapagliflozin 10 mg tablet administered orally once daily + matching placebo for exenatide administered as SC injection once weekly. Patients continued to administer the same type and dose of metformin therapy they were using at study entry.

    Exenatide + Dapagliflozin: Exenatide once weekly (EQW) 2 mg administered as SC injection + dapagliflozin 10 mg tablet administered orally once daily. Patients continued to administer the same type and dose of metformin therapy they were using at study entry.

    Exenatide + Placebo: Exenatide once weekly (EQW) 2 mg administered as SC injection + matching placebo for dapagliflozin tablet administered orally once daily. Patients continued to administer the same type and dose of metformin therapy they were using at study entry.

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Change in HbA1c From Baseline to Week 26.

    Selected primary outcome

    Results · Nov 3, 2026 UTC

    Change in HbA1c From Baseline to Week 26.

    Least-squares mean · percentage of total hemoglobin · Baseline, Week 26

    Analysis population: ITT Population: Randomized patients received at least one dose of study drug. Only patients with non-missing baseline value and at least one non-missing post-baseline value of the response variable were included in analysis.

    Exenatide Once Weekly
    -1.43 percentage of total hemoglobin (clinicaltrials.gov/study/NCT00917267)

    Standard Error: 0.07 (clinicaltrials.gov)

    Overall outcome: 307 Participants (clinicaltrials.gov/study/NCT00917267) analyzed

    Exenatide Twice Daily
    -1.12 percentage of total hemoglobin (clinicaltrials.gov/study/NCT00917267)

    Standard Error: 0.07 (clinicaltrials.gov)

    Overall outcome: 263 Participants (clinicaltrials.gov/study/NCT00917267) analyzed

    Outcome definition & treatment groups

    Change in HbA1c from baseline to Week 26.

    Exenatide Once Weekly: Subcutaneous injection of 2 mg exenatide, once a week

    Exenatide Twice Daily: Subcutaneous injection of exenatide, twice a day (5 mcg exenatide per dose for first 4 weeks, then 10 mcg exenatide per dose for 22 weeks)

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24

    Selected primary outcome

    Results · Nov 4, 2026 UTC

    Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24

    Least-squares mean · percentage of hemoglobin · Baseline, Week 24

    Analysis population: mITT population:all randomized patients who received at least 1 dose;had baseline,at least 1 post-baseline efficacy assessment, irrespective of compliance with study protocol/procedures. Last observation carried forward used. Number of patients analyzed=patients with baseline and at least 1 post-baseline HbA1c assessment during on-treatment period.

    Lixisenatide
    -0.79 percentage of hemoglobin (clinicaltrials.gov/study/NCT00707031)

    Standard Error: 0.053 (clinicaltrials.gov)

    Overall outcome: 295 Participants (clinicaltrials.gov/study/NCT00707031) analyzed

    Exenatide
    -0.96 percentage of hemoglobin (clinicaltrials.gov/study/NCT00707031)

    Standard Error: 0.054 (clinicaltrials.gov)

    Overall outcome: 297 Participants (clinicaltrials.gov/study/NCT00707031) analyzed

    Outcome definition & treatment groups

    Absolute Change = HbA1c value at Week 24 minus HbA1c value at baseline. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 11 (Week 24) or Day 169 if Visit 11 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.

    Lixisenatide: 2-step initiation regimen of lixisenatide.

    Exenatide: 1-step initiation regimen of exenatide.

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Change in Glycosylated Hemoglobin (HbA1c)

    Selected primary outcome

    Results · Nov 6, 2026 UTC

    Change in Glycosylated Hemoglobin (HbA1c)

    Least-squares mean · percentage · Baseline, week 26

    Analysis population: Last Observation Carried Forward; Intent to Treat, computed from the patients having both baseline and post baseline data

    Baseline HbA1c

    Exenatide Arm
    8.13 percentage (clinicaltrials.gov/study/NCT00082381)

    Standard Error: 0.07 (clinicaltrials.gov)

    Overall outcome: 275 Participants (clinicaltrials.gov/study/NCT00082381) analyzed

    Insulin Glargine Arm
    8.19 percentage (clinicaltrials.gov/study/NCT00082381)

    Standard Error: 0.07 (clinicaltrials.gov)

    Overall outcome: 260 Participants (clinicaltrials.gov/study/NCT00082381) analyzed

    Change in HbA1c at week 26

    Exenatide Arm
    -1.00 percentage (clinicaltrials.gov/study/NCT00082381)

    Standard Error: 0.06 (clinicaltrials.gov)

    Overall outcome: 275 Participants (clinicaltrials.gov/study/NCT00082381) analyzed

    Insulin Glargine Arm
    -1.05 percentage (clinicaltrials.gov/study/NCT00082381)

    Standard Error: 0.06 (clinicaltrials.gov)

    Overall outcome: 260 Participants (clinicaltrials.gov/study/NCT00082381) analyzed

    Outcome definition & treatment groups

    Change in HbA1c from baseline to week 26

    Exenatide Arm: Exenatide subcutaneous injection twice daily for 26 weeks (5mcg for 4 weeks followed by 10mcg for 22 weeks)

    Insulin Glargine Arm: Insulin glargine subcutaneous injection once daily for 26 weeks (forced titration to target blood glucose level)

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Change in HbA1c From Baseline to Week 26

    Selected primary outcome

    Results · Oct 14, 2026 UTC

    Change in HbA1c From Baseline to Week 26

    Least-squares mean · percentage of total hemoglobin · Day 1, Week 26

    Analysis population: The ITT Population included randomized subjects who received at least one injection of study medication. Missing data up to Week 26 were imputed using the last observation carried forward (LOCF) approach for subjects who had data for at least one scheduled visit (including Early Termination) subsequent to the baseline measurement.

    Exenatide Once Weekly
    -1.55 percentage of total hemoglobin (clinicaltrials.gov/study/NCT00637273)

    Standard Error: 0.100 (clinicaltrials.gov)

    Overall outcome: 159 Participants (clinicaltrials.gov/study/NCT00637273) analyzed

    Sitagliptin
    -0.92 percentage of total hemoglobin (clinicaltrials.gov/study/NCT00637273)

    Standard Error: 0.099 (clinicaltrials.gov)

    Overall outcome: 162 Participants (clinicaltrials.gov/study/NCT00637273) analyzed

    Pioglitazone
    -1.23 percentage of total hemoglobin (clinicaltrials.gov/study/NCT00637273)

    Standard Error: 0.099 (clinicaltrials.gov)

    Overall outcome: 160 Participants (clinicaltrials.gov/study/NCT00637273) analyzed

    Outcome definition & treatment groups

    Absolute change in HbA1c from baseline (Day 1) to Week 26 \[Week 26 - Baseline\].

    Exenatide Once Weekly: Exenatide once weekly 2 mg subcutaneous weekly plus placebo oral once daily in the morning

    Sitagliptin: Sitagliptin 100 mg oral once daily in the morning plus placebo once weekly subcutaneous weekly

    Pioglitazone: Pioglitazone 45 mg oral once daily in the morning plus placebo once weekly subcutaneous weekly

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Change in Glcosylated Hemoglobin (HbA1c)

    Selected primary outcome

    Results · Oct 30, 2026 UTC

    Change in Glcosylated Hemoglobin (HbA1c)

    Least-squares mean · percentage · baseline, week 52

    Analysis population: Last Observation Carried Forward; Intent to Treat, computed from the patients having both baseline and post-baseline data.

    Baseline HbA1c

    Exenatide Arm
    8.59 percentage (clinicaltrials.gov/study/NCT00082407)

    Standard Error: 0.07 (clinicaltrials.gov)

    Overall outcome: 248 Participants (clinicaltrials.gov/study/NCT00082407) analyzed

    Biphasic Insulin Aspart Arm
    8.65 percentage (clinicaltrials.gov/study/NCT00082407)

    Standard Error: 0.07 (clinicaltrials.gov)

    Overall outcome: 246 Participants (clinicaltrials.gov/study/NCT00082407) analyzed

    Change in HbA1c at week 52

    Exenatide Arm
    -0.98 percentage (clinicaltrials.gov/study/NCT00082407)

    Standard Error: 0.07 (clinicaltrials.gov)

    Overall outcome: 248 Participants (clinicaltrials.gov/study/NCT00082407) analyzed

    Biphasic Insulin Aspart Arm
    -0.88 percentage (clinicaltrials.gov/study/NCT00082407)

    Standard Error: 0.07 (clinicaltrials.gov)

    Overall outcome: 246 Participants (clinicaltrials.gov/study/NCT00082407) analyzed

    Outcome definition & treatment groups

    Change in HbA1c from baseline to week 52

    Exenatide Arm: subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 48 weeks

    Biphasic Insulin Aspart Arm: subcutaneous injection, twice daily; titration to target blood glucose level

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Change in Glycosylated Hemoglobin (HbA1c)

    Selected primary outcome

    Results · Oct 30, 2026 UTC

    Change in Glycosylated Hemoglobin (HbA1c)

    Least-squares mean · Percentage of glycosylated hemoglobin · Baseline and 26 weeks

    Analysis population: All randomized patients who were previously treated with metformin only and who received at least one dose of study drug (MET only, FAS) and had baseline and at least one post-baseline value available

    Exenatide Twice Daily
    -1.00 Percentage of glycosylated hemoglobin (clinicaltrials.gov/study/NCT00434954)

    Standard Error: 0.05 (clinicaltrials.gov)

    Overall outcome: 181 Participants (clinicaltrials.gov/study/NCT00434954) analyzed

    Premixed Insulin Aspart Twice Daily
    -1.14 Percentage of glycosylated hemoglobin (clinicaltrials.gov/study/NCT00434954)

    Standard Error: 0.05 (clinicaltrials.gov)

    Overall outcome: 173 Participants (clinicaltrials.gov/study/NCT00434954) analyzed

    Outcome definition & treatment groups

    Change in HbA1c from baseline after 26 weeks of treatment (i.e., HbA1c at week 26 minus HbA1c at week 0)

    Exenatide Twice Daily: Exenatide 5 mcg twice daily for 4 weeks, followed by 10 mcg twice daily for 26 weeks

    Premixed Insulin Aspart Twice Daily: Premixed insulin aspart (70% protamin crystallized, 30% soluble) twice daily, individually titrated to reach target blood glucose levels for 26 weeks

    One of 2 registered primary outcomes, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Change in HbA1c From Baseline to Week 26

    Selected primary outcome

    Results · Nov 6, 2026 UTC

    Change in HbA1c From Baseline to Week 26

    Least-squares mean · percentage of total hemoglobin · Baseline, Week 26

    Analysis population: ITT Population: All randomized patients who had taken at least one dose of study drug. Only patients with non-missing baseline value and at least one non-missing post-baseline value of the response variable were included in analysis.

    Exenatide Once Weekly
    -1.47 percentage of total hemoglobin (clinicaltrials.gov/study/NCT00641056)

    Standard Error: 0.05 (clinicaltrials.gov)

    Overall outcome: 205 Participants (clinicaltrials.gov/study/NCT00641056) analyzed

    Insulin Glargine
    -1.31 percentage of total hemoglobin (clinicaltrials.gov/study/NCT00641056)

    Standard Error: 0.06 (clinicaltrials.gov)

    Overall outcome: 206 Participants (clinicaltrials.gov/study/NCT00641056) analyzed

    Outcome definition & treatment groups

    Change in HbA1c from baseline to Week 26

    Exenatide Once Weekly: Patients assigned to the Exenatide Once Weekly group received a 2 mg dose of exenatide injected once a week.

    Insulin Glargine: Patients assigned to the Insulin Glargine group started insulin glargine treatment with 10 units per day, utilizing the INITIATE (Initiate Insulin by Aggressive Titration and Education) dosing and were instructed to adjust insulin doses to achieve a target blood glucose of 4.0-5.5 mmol/L.

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

  • Primary outcome: Change in HbA1c From Baseline to Week 28

    Selected primary outcome

    Results · Nov 6, 2026 UTC

    Change in HbA1c From Baseline to Week 28

    Least-squares mean · Percentage of HbA1c · Baseline to Week 28

    Analysis population: The ITT analysis set included all randomized participants who received at least 1 dose of study medication and had at least 1 post-baseline HbA1c assessment. Only participants with data available for analysis are presented.

    Exenatide
    -0.96 Percentage of HbA1c (clinicaltrials.gov/study/NCT02229383)

    95% Confidence Interval: -1.12 to -0.81 (clinicaltrials.gov)

    Overall outcome: 230 Participants (clinicaltrials.gov/study/NCT02229383) analyzed

    Placebo
    -0.22 Percentage of HbA1c (clinicaltrials.gov/study/NCT02229383)

    95% Confidence Interval: -0.38 to -0.07 (clinicaltrials.gov)

    Overall outcome: 228 Participants (clinicaltrials.gov/study/NCT02229383) analyzed

    Outcome definition & treatment groups

    To compare the change from baseline in HbA1c achieved with exenatide once weekly (EQW) added to titrated basal insulin glargine to placebo added to titrated basal insulin glargine, with or without metformin, after 28 weeks of double-blind treatment. SU= sulfonylurea.

    Exenatide: Exenatide 2 mg 1 time per week + titrated basal insulin glargine with or without metformin.

    Placebo: Placebo (matching with exenatide) 1 time per week + titrated basal insulin glargine with or without metformin.

    One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov (clinicaltrials.gov).

Source: ClinicalTrials.gov API v2 (clinicaltrials.gov/search) · as of Nov 17, 2026

All trials on ClinicalTrials.gov (clinicaltrials.gov)
FDA enforcement archive

Recall records

Enforcement records describe specific recalled products and lots. They do not establish the recall status of every product containing the ingredient. openFDA does not maintain current recall status after classification; read the FDA record and any manufacturer notice for details.

1 indexed product record, ordered by FDA report date. One recall event may include several products.

D-0868-2026

Class IIFDA report: Sep 30, 2026

Recalling firm: Amneal Pharmaceuticals of New York, LLC

Exenatide Injection, USP, 250 mcg/mL, 1.2 mL per prefilled pen, Rx Only, Subcutaneous Use Only, For Single Patient Use Only, Manufactured by: Amneal Pharmaceuticals Pvt. Ltd., Ahmedabad 382213, India; Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08807, NDC 70121-1685-1

Reason for recall

Defective Delivery System: Possibility of no medication in the prefilled pen.

FDA record & affected lots (api.fda.gov)Record retrieved Nov 12, 2026

Browse the FDA enforcement archive (accessdata.fda.gov) · Source coverage & limitations (open.fda.gov)

Related

Related GLP-1s to compare

Updated automatically

What changed for Exenatide

  • TrialExenatide study now completed (was active, not recruiting): Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol (clinicaltrials.gov/study/NCT00679042)
  • PriceGoodRx: Generic exenatide (Amneal) now ~$422 per pen (was ~$447 per pen) (read on goodrx.com)
  • RecallRecall: Exenatide Injection, USP, 250 mcg/mL, 1.2 mL per prefilled pen (api.fda.gov/drug/enforcement.json)
  • FDA labelFDA label updated: Exenatide (Amneal Pharmaceuticals LLC), effective 2026-05-27 (api.fda.gov/drug/label.json)
  • FDAFDA approved a labeling supplement for Byetta (accessdata.fda.gov/scripts/cder/daf/index.cfm)
  • FDAFDA approved a labeling supplement for Byetta (accessdata.fda.gov/scripts/cder/daf/index.cfm)
  • FDAFDA approved a labeling supplement for Bydureon Bcise (accessdata.fda.gov/scripts/cder/daf/index.cfm)
  • FDAFDA approved a labeling supplement for Bydureon (accessdata.fda.gov/scripts/cder/daf/index.cfm)

Written from each source's own record as it changes. Every change on GLPcompare

ClinicalTrials.gov

What Exenatide is studied for

Registered trials of this medicine by condition. A trial shows a question being asked, not that the answer is yes.

From PubMed

Latest Exenatide trials and reviews

  • Expression of Concern: Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial (pubmed.ncbi.nlm.nih.gov/42330995)

    Randomized trial · Lancet · Jun 22, 2026 · The Editors Of The Lancet.

  • Effects of insulin and exenatide therapy on glycemic control and β-cell function in patients newly diagnosed with type 2 diabetes and severe hyperglycemia (pubmed.ncbi.nlm.nih.gov/42290292)

    Randomized trial · J Chin Med Assoc · Jun 15, 2026 · Wu TH et al.

  • The GLP-1 Agonist Exenatide Is Associated with Improved Adherence to Health Behavior and Lifestyle Treatment in Adolescents with Obesity: A Randomized Controlled Trial (pubmed.ncbi.nlm.nih.gov/42228680)

    Randomized trial · Obes Facts · Jun 2, 2026 · Stenlid R et al.

  • Exenatide induces an enhanced endogenous glucagon-like peptide-1 secretory response in patients receiving basal insulin (pubmed.ncbi.nlm.nih.gov/41604435)

    Randomized trial · J Clin Endocrinol Metab · Jun 1, 2026 · Parikh M et al.

  • Liraglutide and Exenatide in Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Cognitive Outcomes (pubmed.ncbi.nlm.nih.gov/41599176)

    Meta-analysis · Pharmaceutics · Jan 4, 2026 · Santos P et al.

  • Efficacy of the Combination of Exenatide and Dapagliflozin in the Management of Diabetes and Weight Control: A Network Meta-Analysis (pubmed.ncbi.nlm.nih.gov/41187775)

    Meta-analysis · Horm Metab Res · Nov 4, 2025 · Abuali A et al.

  • New developments in GLP-1 agonist therapy for gestational diabetes: Systematic review on liraglutide, semaglutide, and exenatide from ClinicalTrials.gov (pubmed.ncbi.nlm.nih.gov/41054173)

    Systematic review · Medicine (Baltimore) · Oct 1, 2025 · Alshehri FS. · cited by 4

  • Changes in β-Cell Function and Insulin Sensitivity During Treatment With Dapagliflozin Alone or in Combination With Exenatide in Type 2 Diabetes (pubmed.ncbi.nlm.nih.gov/40627548)

    Randomized trial · Diabetes Care · Sep 1, 2025 · Triplitt C et al. · cited by 4

Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.

Questions

Common questions about Exenatide

What is the brand name of exenatide?
Exenatide is sold in the US as Generic exenatide. A compounded version has no brand name and is not FDA-approved.
Is Exenatide in shortage?
No matching shortage record was returned in the latest complete FDA check. Last complete check: Nov 17, 2026. Confirm local stock with your pharmacy. Source (accessdata.fda.gov)
Is there a generic exenatide?
Not any more. FDA approved a generic of Byetta from Amneal EU on Nov 19, 2024, and it is now listed as discontinued. So is Byetta itself. No. Bydureon itself is listed as discontinued, and FDA has not approved a generic of it. Source
How much does Exenatide cost per month?
Among the sourced FDA-approved offers in our catalog, a tracked starting quote is ~$422 per pen for Generic exenatide (Amneal) via GoodRx. Days of supply not on record; not ranked per 30 days.. GoodRx coupon, lowest listed price for one 5 mcg pen (60 doses: 30 days at the twice-daily dose) Every exenatide product is now discontinued: the FDA withdrew the Byetta and Bydureon approvals in 2025, and Amneal's generic is listed by the FDA as discontinued too. Pharmacies may still dispense remaining stock. No separate quote at the cited trial dose is verified. Starting and trial-dose quotes may cover different products. These are self-pay offers, not insurance estimates or a guarantee of eligibility. Source (goodrx.com)
How much weight can you lose on Exenatide?
In its pivotal trial (DURATION-1), Exenatide at 2 mg weekly (Bydureon) showed a mean body-weight change of -4.1 kg (~4% of the 102 kg baseline) at 52 wks. This is a trial average; individual results vary. Source (diabetesjournals.org)
What is Exenatide approved for?
Approved uses across Exenatide products include type 2 diabetes. Indications differ by brand and formulation; this does not mean every product is approved for every use. See the product-specific prescribing information above.